<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2019 | Cochrane Library</title> <meta content="Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002217.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002217.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD002217.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review" name="citation_title"/> <meta content="Sarah J Nevitt" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="sjn16@liverpool.ac.uk" name="citation_author_email"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD002217.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/07/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002217.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002217.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD002217.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [adverse effects, *therapeutic use]; Carbamazepine [therapeutic use]; Epilepsies, Partial [*drug therapy]; Epilepsy, Tonic‐Clonic [*drug therapy]; Induction Chemotherapy; Phenobarbital [adverse effects, *therapeutic use]; Phenytoin [*therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Seizures [*drug therapy]; Time Factors; Valproic Acid [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD002217.pub3&amp;doi=10.1002/14651858.CD002217.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD002217\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD002217\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD002217.pub3",title:"Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review",firstPublishedDate:"Jul 31, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002217.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002217.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD002217.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD002217.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002217.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD002217.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD002217.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD002217.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD002217.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD002217.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1932 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD002217.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0104"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-sec-0098"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/appendices#CD002217-sec-0109"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/table_n/CD002217StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/table_n/CD002217StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#CD002217-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sarah J Nevitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#CD002217-cr-0003">Catrin Tudur Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information#CD002217-cr-0004">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information/en#CD002217-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 July 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD002217.pub3">https://doi.org/10.1002/14651858.CD002217.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD002217-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002217-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002217-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002217-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002217-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002217-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD002217-abs-0001" lang="en"> <section id="CD002217-sec-0001"> <h3 class="title" id="CD002217-sec-0001">Background</h3> <p>This is an update of a Cochrane Review first published in 2001, and last updated in 2013. This review is one in a series of Cochrane Reviews investigating pair‐wise monotherapy comparisons. </p> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure‐free and go into long‐term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy. </p> <p>Worldwide, particularly in the developing world, phenytoin and phenobarbitone are commonly used antiepileptic drugs, primarily because they are inexpensive. The aim of this review is to summarise data from existing trials comparing phenytoin and phenobarbitone. </p> </section> <section id="CD002217-sec-0002"> <h3 class="title" id="CD002217-sec-0002">Objectives</h3> <p>To review the time to treatment failure, remission and first seizure with phenobarbitone compared with phenytoin when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> <section id="CD002217-sec-0003"> <h3 class="title" id="CD002217-sec-0003">Search methods</h3> <p>For the latest update, we searched the following databases on 21 August 2018: the Cochrane Register of Studies (CRS Web), which includes Cochrane Epilepsy's Specialized Register and CENTRAL; MEDLINE; the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov); and the World Health Organization International Clinical Trials Registry Platform (ICTRP). We handsearched relevant journals and contacted pharmaceutical companies, original trial investigators, and experts in the field.  </p> </section> <section id="CD002217-sec-0004"> <h3 class="title" id="CD002217-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing monotherapy with either phenobarbitone or phenytoin in children or adults with focal onset seizures or generalised onset tonic‐clonic seizures. </p> </section> <section id="CD002217-sec-0005"> <h3 class="title" id="CD002217-sec-0005">Data collection and analysis</h3> <p>This was an individual participant data (IPD), review. Our primary outcome was time to treatment failure. Our secondary outcomes were time to first seizure post‐randomisation, time to six‐month remission and time to 12‐month remission. We used Cox proportional hazards regression models to obtain trial‐specific estimates of hazard ratios (HRs), with 95% confidence intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI. </p> </section> <section id="CD002217-sec-0006"> <h3 class="title" id="CD002217-sec-0006">Main results</h3> <p>Individual participant data were obtained for five studies, which recruited a total of 635 participants, representing 80% of 798 individuals from all seven identified eligible trials. For remission outcomes, an HR of less than 1 indicates an advantage for phenytoin and for first seizure and treatment failure outcomes an HR of less than 1 indicates an advantage for phenobarbitone. </p> <p>Results for the primary outcome of the review were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type for 499 participants: 1.61, 95% CI 1.22 to 2.12, low‐certainty evidence), time to treatment failure due to adverse events (pooled HR adjusted for seizure type for 499 participants: 1.99, 95% CI 1.37 to 2.87, low‐certainty evidence), time to treatment failure due to lack of efficacy (pooled HR adjusted for seizure type for 499 participants: 1.87, 95% CI 1.32 to 2.66, moderate‐certainty evidence), showing a statistically significant advantage for phenytoin compared to phenobarbitone. </p> <p>For our secondary outcomes, we did not find any statistically significant differences between phenytoin and phenobarbitone: time to first seizure post‐randomisation (pooled HR adjusted for seizure type for 624 participants: 0.85, 95% CI 0.69 to 1.06, moderate‐certainty evidence), time to 12‐month remission (pooled HR adjusted for seizure type for 588 participants: 0.90, 95% CI 0.69 to 1.19, moderate‐certainty evidence), and time to six‐month remission pooled HR adjusted for seizure type for 588 participants: 0.91, 95% CI 0.71 to 1.15, moderate‐certainty evidence). </p> <p>For individuals with focal onset seizures (73% of individuals contributing to analysis), numerical results were similar and conclusions the same as for analyses of all individuals and for individuals with generalised onset seizures (27% of individuals contributing to analysis), results were imprecise and no clear differences between the drugs were observed. </p> <p>Several confounding factors, most notably the differences in design of the trials with respect to blinding, were likely to have impacted on the results of the primary outcome 'time to treatment failure', and in turn, the treatment failure rates may have impacted on the secondary efficacy outcomes of time to first seizure and time to 12‐month and six‐month remission. </p> </section> <section id="CD002217-sec-0007"> <h3 class="title" id="CD002217-sec-0007">Authors' conclusions</h3> <p>Low‐certainty evidence from this review suggests that phenytoin may be a more effective drug than phenobarbitone in terms of treatment retention (treatment failures due to lack of efficacy or adverse events or both). Moderate‐certainty evidence from this review also indicates no differences between the drugs in terms of time to seizure recurrence and seizure remission. </p> <p>However, the trials contributing to the analyses had methodological inadequacies and methodological design differences that may have impacted upon the results of this review. Therefore, we do not suggest that results of this review alone should form the basis of a treatment choice for a patient with newly onset seizures. We recommend that future trials should be designed to the highest quality possible with consideration of masking, choice of population, classification of seizure type, duration of follow‐up, choice of outcomes and analysis, and presentation of results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD002217-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD002217-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD002217-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD002217-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD002217-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD002217-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD002217-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD002217-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD002217-abs-0005" lang="en"> <h3>Phenobarbitone versus phenytoin monotherapy (single‐drug treatment) for epilepsy</h3> <p>This is an updated version of the Cochrane Review previously published in 2013, Issue 1 of the <i>Cochrane Database of Systematic Reviews</i>. </p> <p><b>Background</b> </p> <p>Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation), and move from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control generalised onset or focal onset seizures. </p> <p>This review applies to people with focal seizures (with or without secondary generalisation) and people with generalised tonic‐clonic seizures, a specific generalised seizure type. This review does not apply to people with other generalised seizure types such as absence seizures or myoclonic seizures, as the recommended treatments for these seizure types are different. </p> <p>Worldwide, particularly in low‐ and middle‐income countries in Africa, Asia, and South America, phenobarbitone and phenytoin are commonly used antiepileptic drugs due to the low cost of these drugs. </p> <p><b>Objective</b> </p> <p>The aim of this review was to compare how effective these drugs are at controlling seizures, to find out if they are associated with side effects that may result in individuals stopping the medication, and to inform a choice between these medications. </p> <p><b>Methods</b> </p> <p>The last search for trials was in August 2018. We assessed the evidence from seven clinical trials in which people received either phenobarbitone or phenytoin and their treatment was decided randomly. We were able to combine data for 635 people from five of the seven trials; for the remaining 163 people from two trials, data were not available to use in this review </p> <p><b>Key results</b> </p> <p>This review found no evidence to suggest a difference between phenobarbitone and phenytoin in terms of the time to seizure recurrence and time to seizure remission (seizure free period of six or 12 months). Phenobarbitone treatment was more likely to be withdrawn than phenytoin treatment, however, this may have been influenced by the design of the included studies (whether the people and the clinicians treating them knew which treatment the person was receiving). </p> <p><b>Quality of the evidence</b> </p> <p>Some of the trials contributing data to the review had methodological problems, which may have introduced bias and inconsistent results into this review. Also, we believe that the difference in study design with regards to whether the treatment was masked from the patients and clinicians (e.g. with a placebo tablet) had an impact on the rates of withdrawal from the study treatments, which also is likely to have impacted on the outcomes related to seizure control </p> <p>These problems may have affected the results of this review and we judged the quality of the evidence provided by this review to be moderate to low quality. We do not suggest using the results of this review alone for making a choice between phenytoin or phenobarbitone for the treatment of epilepsy. Future trials comparing these drugs or any other antiepileptic drugs should be designed using high‐quality methods to ensure results are also of high quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD002217-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD002217-sec-0104"></div> <h3 class="title" id="CD002217-sec-0105">Implications for practice</h3> <section id="CD002217-sec-0105"> <p>Current UK guidelines recommend carbamazepine or lamotrigine as first‐line treatment for adults and children with new onset focal seizures and sodium valproate for adults and children with new onset generalised seizures (<a href="https://archie.cochrane.org/sections/documents/view?version=z1810161445427693100361160184097%26format=REVMAN#REF-NICE-2012" target="_blank">NICE 2012</a>). Results of this review do not refute or support these guidelines. </p> <p>The results of this review do not provide evidence on which a choice can be made between phenytoin and phenobarbitone with respect to seizure control. Phenytoin is significantly less likely to be failed as a treatment, which may make it the preferred choice of the two drugs compared in this review. </p> <p>However, as the trials contributing to the analyses had methodological inadequacies and inconsistencies, particularly trial design differences, with respect to blinding, which may have had an impact on the certainty of the evidence provided by this review. Therefore, we do not suggest that results of this review alone should form the basis of a treatment choice for a patient with newly onset seizures. We encourage caution in the use of these drugs in women of child‐bearing potential because of documented teratogenic effects, where the risk is estimated to be two to three times that of the general population (<a href="./references#CD002217-bbs2-0018" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2] ">Bromley 2014</a>; <a href="./references#CD002217-bbs2-0040" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1‐13. ">Meador 2008</a>; <a href="./references#CD002217-bbs2-0042" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry2006;77(2):193‐8. ">Morrow 2006</a>; <a href="./references#CD002217-bbs2-0067" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton‐SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2] ">Weston 2016</a>). </p> </section> <h3 class="title" id="CD002217-sec-0106">Implications for research</h3> <section id="CD002217-sec-0106"> <p>Few consistent differences in efficacy have been found between these two commonly used antiepileptic drugs in individual trials. The methodological quality of trials comparing these two drugs has been variable, producing variable individual trial results introducing heterogeneity into the pooled results of this review and therefore making the pooled results difficult to interpret. If there are differences in efficacy and tolerability across heterogeneous populations of individuals such as those studied here, it is likely that these differences are small. It has been argued that future comparative antiepileptic drug trials should be powered to establish equivalence (<a href="./references#CD002217-bbs2-0031" title="JonesB , JarvisP , LewisJA , EbuttAF . Trials to assess equivalence; the importance of rigorous methods. BMJ1996;313:36‐9. ">Jones 1996</a>), and therefore be capable of detecting what is considered to be the smallest important clinical difference. </p> <p>This review highlights the need for the design of future antiepileptic drug monotherapy trials that recruit individuals with specific epilepsy syndromes to be powered to detect a difference between particular antiepileptic drugs. An approach likely to reflect and inform clinical practice, as well as being statistically powerful, would be to recruit heterogeneous populations for whom epilepsy syndromes have been adequately defined, with testing for interaction between treatment and epilepsy syndrome. In view of potential problems of misclassification, syndromes will have to be well‐defined, with adequate checking mechanisms to ensure that classifications are accurate and a system to recognise uncertainty surrounding epilepsy syndromes in individuals within trials. It is also important that future trials are of a sufficient duration to measure long‐term effectiveness of antiepileptic drugs (treatments that will be life‐long for many individuals with epilepsy), as well as psychosocial, quality‐of‐life and health economic outcomes. </p> <p>Consideration is also required in the design of a trial regarding whether to blind participants and outcome assessors to treatment allocation. While an open‐label design is a more pragmatic and practical approach for large long‐term trials, when trials involve drugs with documented adverse‐event profiles, such as phenobarbitone, masking of treatment may be important to avoid preconceptions of the drug being more likely to be associated with serious adverse events, which the results of this review did not show. </p> <p>The choice of outcomes at the design stage of a trial and the presentation of the results of outcomes, particularly of a time‐to‐event nature, require very careful consideration. While the majority of trials of a monotherapy design record an outcome measuring efficacy (seizure control), and an outcome measuring tolerability (adverse events), there is little uniformity between the definition of the outcomes and the reporting of the summary statistics related to the outcomes (<a href="./references#CD002217-bbs2-0053" title="NolanSJ , SuttonL , MarsonA , Tudur SmithC . Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. Better knowledge for better health. 21st Cochrane Colloquium. Quebec City, Canada: The Cochrane Collaboration, 2013 September 19‐23:114‐5. ">Nolan 2013a</a>), making an aggregate data approach to meta‐analysis in reviews of monotherapy trials impossible. Where trial authors cannot or will not make individual participant data (IPD), available for analysis, we are left with no choice but to exclude a proportion of relevant evidence from the review, which will impact upon the interpretation of results of the review and applicability of the evidence and conclusions. The International League Against Epilepsy recommends that trials of a monotherapy design should adopt a primary effectiveness outcome of 'time to treatment failure (retention time)' and should be of a duration of at least 48 weeks to allow for assessment of longer‐term outcomes, such as remission (<a href="./references#CD002217-bbs2-0029" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799. ">ILAE 1998</a>; <a href="./references#CD002217-bbs2-0030" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: evidence‐based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). If trials followed these recommendations, an aggregate data approach to meta‐analysis may be feasible, reducing the resources and time required from an IPD approach. </p> <p>A network meta‐analysis has also been published (<a href="./references#CD002217-bbs2-0044" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonAG . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>), comparing all direct and indirect evidence from phenobarbitone, phenytoin, and other standard and new antiepileptic drugs licensed for monotherapy. This network meta‐analysis will be updated as more information becomes available; however, we acknowledge that as both phenobarbitone and phenytoin are no longer considered to be a first‐line agent for newly diagnosed individuals, in favour of newer agents, such as lamotrigine and levetiracetam, it is unlikely that a substantial amount of new evidence will become available for this review. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD002217-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD002217-sec-0029"></div> <div class="table" id="CD002217-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly onset focal or generalised epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> phenobarbitone </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenobarbitone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants<sup>a</sup> </i> </p> <p>Range of follow‐up: 0 to 4653 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2135 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 681 days (1454 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.61</b> </p> <p>(1.22 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 1.99, 95% CI 1.37 to 2.87, P = 0.0003, I² = 58%), and due to lack of efficacy (HR 1.87, 95% CI 1.32 to 2.66, P = 0.0005, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4653 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1300 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 540 days (760 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.46</b> </p> <p>(1.09 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 1.86, 95% CI 1.27 to 2.73, P = 0.001, I²=73%), and due to lack of efficacy (HR 1.73 95% CI 1.19 to 2.52, P = 0.004, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 4272 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 10th percentile<sup>d</sup> </p> <p>of time to treatment failure was 778 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 10th percentile<sup>d</sup> of time to treatment failure was 189 days (589 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 4.04</b> (1.61 to 10.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 4.60, 95% CI 1.17 to 17.98, P = 0.03, I²=0%), and due to lack of efficacy (HR 3.40, 95% CI 1.21 to 9.54, P = 0.02, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Illustrative risks in the phenobarbitone and phenytoin groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p><b>CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty (quality):</b> Further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty (quality):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty (quality):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very certainty (quality):</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled HR for all participants adjusted for seizure type. All pooled HRs calculated with fixed effects </p> <p>b. Downgraded once for risk of bias: risk of bias judged as high for three unblinded studies as lack of masking may have influenced the withdrawal rates of phenobarbitone </p> <p>c. Downgraded once for inconsistency: Substantial heterogeneity present between studies (I² = 53%); when results are repeated with random effects, confidence intervals around pooled results are fairly wide. Inconsistency may be due to combining studies of an open‐label and double‐blind design. </p> <p>d. The 10th percentile of time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures, as fewer than 50% of participants failed/withdrew from treatment we could not calculate median time. </p> <p>e. Downgraded once for imprecision: the subgroup of participants with generalised onset tonic‐clonic seizures is relatively small (19% of total participants) and confidence intervals around pooled results are fairly wide. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD002217-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly onset focal or generalised epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> phenobarbitone </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenobarbitone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>All participants<sup>a</sup> </i> </p> <p>Range of follow‐up: 0 to 4589 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 108 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 186 days (78 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.87</b> </p> <p>(0.70 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4589 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 74 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 116 days (42 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.81</b> </p> <p>(0.63 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 1 to 4035 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 322 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 439 days (117 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.06</b> </p> <p>(0.70 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4061 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 481 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 483</p> <p>days (2 days longer) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.90</b> </p> <p>(0.69 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4061 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 515 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 483</p> <p>days (32 days shorter) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.96</b> </p> <p>(0.70 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 8 to 3869 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 375 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 421</p> <p>days (46 days shorter) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.77</b> </p> <p>(0.46 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 studies)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Illustrative risks in the phenobarbitone and phenytoin groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12‐months of remission) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty (quality):</b> Further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty (quality):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty (quality):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very certainty (quality):</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled HR for all participants adjusted for seizure type. All pooled HRs calculated with fixed effects </p> <p>b. Downgraded once for risk of bias: risk of bias judged as high for three unblinded studies as lack of masking may have influenced the withdrawal rates of phenobarbitone </p> <p>c. The HR for individuals with generalised seizures is not estimable from one of the trials as only one participant achieved 12‐month remission </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD002217-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD002217-sec-0030"></div> <p>This is an updated version of the Cochrane Review previously published in 2013, Issue 1 of the <i>Cochrane Database of Systematic Reviews</i> (<a href="./references#CD002217-bbs2-0072" title="NolanSJ , Tudur SmithC , PulmanJ , MarsonAG . Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2] ">Nolan 2013b</a>). </p> <section id="CD002217-sec-0031"> <h3 class="title" id="CD002217-sec-0031">Description of the condition</h3> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. Epilepsy is a disorder of many heterogenous seizure types, with an estimated incidence of 33 to 57 per 100,000 person‐years worldwide (<a href="./references#CD002217-bbs2-0015" title="AnnegersJF , DubinskyS , CoanSP , NewmarkME , RohtL . The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia1999;40(4):502‐6. ">Annegers 1999</a>; <a href="./references#CD002217-bbs2-0028" title='HirtzD , ThurmanDJ , Gwinn‐HardyK , MohamedM , ChaudhuriAR , ZalutskyR . How common are the "common" neurologic disorders?. Neurology2007;68:326‐37. '>Hirtz 2007</a>; <a href="./references#CD002217-bbs2-0037" title="MacDonaldBK , JohnsonAL , GoodridgeDM , CockerellOC , SanderJW , ShorvonSD . Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology2000;48:833‐41. ">MacDonald 2000</a>; <a href="./references#CD002217-bbs2-0055" title="OlafssonE , LudvigssonP , GudmundssonG , HesdorferD , KjartanssonO , HauserWA . Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology2005;4:627‐34. ">Olafsson 2005</a>; <a href="./references#CD002217-bbs2-0059" title="SanderJW , ShorvonSD . Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry1996;61(5):433‐43. ">Sander 1996</a>), accounting for approximately 1% of the global burden of disease (<a href="./references#CD002217-bbs2-0043" title="MurrayCJ , LopezAD . Global Comparative Assessments in the Health Sector. World Health Organization, 1994. ">Murray 1994</a>). </p> <p>The lifetime risk of epilepsy onset is estimated to be 1300 to 4000 per 100,000 person‐years (<a href="./references#CD002217-bbs2-0025" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD002217-bbs2-0032" title="Juul‐JensonP , FoldspangA . Natural history of epileptic seizures. Epilepsia1983;24:297‐312. ">Juul‐Jenson 1983</a>), and the lifetime prevalence could be as large as 70 million people worldwide (<a href="./references#CD002217-bbs2-0051" title="NgugiAK , BottomleyC , KleinschmidtI , SanderJW , NewtonCR . Estimation of the burden of active and life‐time epilepsy: a meta‐analytic approach. Epilepsia2010;51(5):883‐90. ">Ngugi 2010</a>). It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to go into long‐term remission shortly after starting drug therapy (<a href="./references#CD002217-bbs2-0020" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>; <a href="./references#CD002217-bbs2-0025" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD002217-bbs2-0060" title="SanderJW . The use of anti‐epileptic drugs ‐ principles and practice. Epilepsia2004;45(6):28‐34. ">Sander 2004</a>), and around 70% of individuals can achieve seizure freedom using a single antiepileptic drug in monotherapy (<a href="./references#CD002217-bbs2-0020" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>). Current National Institute for Health and Care Excellence (NICE), guidelines recommend that both adults and children with epilepsy should be treated with monotherapy, wherever possible (<a href="./references#CD002217-bbs2-0052" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence. Clinical Guidance 137; available from: https://www.nice.org.uk/guidance/cg137/resources/epilepsies‐diagnosis‐and‐management‐35109515407813 (accessed 18 December 2018).2012. ">NICE 2012</a>). The remaining 30% of individuals experience refractory or drug‐resistant seizures, which often require treatment with combinations of antiepileptic drugs or alternative treatments, such as epilepsy surgery (<a href="./references#CD002217-bbs2-0034" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342:314‐9. ">Kwan 2000</a>). </p> <p>We studied two seizure types in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move throughout the brain, and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). </p> </section> <section id="CD002217-sec-0032"> <h3 class="title" id="CD002217-sec-0032">Description of the intervention</h3> <p>Phenobarbitone and phenytoin are two of the earliest drugs licensed for the treatment of epileptic seizures and have been used as monotherapy for focal seizures and generalised tonic‐clonic seizures for over 50 years (<a href="./references#CD002217-bbs2-0011" title="GruberCM , BrockJT . Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital and methylphenylhydantoin in motor seizures. Clinical Pharmacology and Therapeutics1962;3(1):23‐8. ">Gruber 1962</a>). </p> <p>Phenobarbitone and phenytoin are no longer considered as first‐line agents in the USA and much of Europe due to worries over short‐ and long‐term tolerability (<a href="./references#CD002217-bbs2-0064" title="TrimbleMR , CullC . Children of school age: the influence of antiepileptic drugs on behavior and intellect. Epilepsia1988;29(Suppl 3):S15‐9. ">Trimble 1988</a>; <a href="./references#CD002217-bbs2-0066" title="WallaceH , ShorvonSD , HopkinsA , O'DonoghueM . Guidelines for the Clinical Management of Adults with Poorly Controlled Epilepsy. London: Royal College of Physicians, 1997. ">Wallace 1997</a>; <a href="./references#CD002217-bbs2-0068" title="WilderBJ . Phenytoin: clinical use. Antiepileptic Drugs. 4th edition. New York:: Raven Press, 1995:339‐44. ">Wilder 1995</a>). One open‐label paediatric trial in the UK (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>), withdrew the phenobarbitone arm of the trial because of concerns about behavioural problems and difficulties getting paediatricians to randomise individuals. However, the largest reported randomised controlled trial (RCT), investigating phenobarbitone as monotherapy in adults with focal seizures (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>), did not find phenobarbitone to be more associated with adverse events than other trial drugs (carbamazepine, phenytoin, and primidone). In fact, phenobarbitone was significantly associated with the lowest incidence of motor disturbances (ataxia (lack of voluntary coordination of muscle movements), incoordination, nystagmus, and tremor), and gastrointestinal problems. </p> <p>However both drugs are still used as first‐line drugs in low‐ and middle‐income countries in Africa, Asia, and South America, primarily because they are inexpensive (<a href="./references#CD002217-bbs2-0016" title="BanuSH , JahanM , KoliUK , FerdousiS , KhanNZ , NevilleB . Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ2007;334(7605):1207. ">Banu 2007</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). A paediatric trial conducted in rural India (<a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>), comparing phenobarbitone with phenytoin, found no excess in behavioural side effects from phenobarbitone, but a trial in Nigerian adults (<a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>), showed evidence of an association between phenobarbitone and worsening of cognitive impairments, particularly memory deficits. </p> <p>Both phenobarbitone and phenytoin have been shown to have teratogenic (disturbances to foetal development), effects (<a href="./references#CD002217-bbs2-0018" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2] ">Bromley 2014</a>; <a href="./references#CD002217-bbs2-0067" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton‐SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2] ">Weston 2016</a>), where the risk is estimated to be two to three times that of the general population (<a href="./references#CD002217-bbs2-0040" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1‐13. ">Meador 2008</a>; <a href="./references#CD002217-bbs2-0042" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry2006;77(2):193‐8. ">Morrow 2006</a>). </p> <p>Phenobarbitone is associated with low folic acid levels and megaloblastic anaemia (anaemia characterised by many large immature and dysfunctional red blood cells; <a href="./references#CD002217-bbs2-0040" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1‐13. ">Meador 2008</a>). In addition to concerns over behavioural and cognitive adverse events, phenobarbitone is commonly associated with somnolence (sedation), and connective tissue abnormalities, such as Dupuytren's contracture and frozen shoulder (<a href="./references#CD002217-bbs2-0017" title="BaulacM , CramerJA , MattsonRH . Phenobarbital and other barbiturates: adverse effects. In: LevyRH , MattsonRH , MeldrumBS , et al. editor(s). Antiepileptic Drugs. 5. Philadelphia: Lippincott Williams &amp; Wilkins, 2002:528‐40. ">Baulac 2002</a>), and exposure to phenobarbitone has also been shown to be associated with significantly higher rates of cardiac malformations compared to exposure to other antiepileptic drugs during pregnancy in a recent systematic review (<a href="./references#CD002217-bbs2-0067" title="WestonJ , BromleyR , JacksonCF , AdabN , Clayton‐SmithJ , GreenhalghJ , et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD010224.pub2] ">Weston 2016</a>). </p> <p>Phenytoin is associated with long‐term cosmetic changes including gum hyperplasia, acne and coarsening of the facial features (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0062" title="ScheinfeldN . Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatology Online Journal2003;9(3):6. ">Scheinfeld 2003</a>), as well as low folic acid levels, predisposing participants to megaloblastic anaemia (<a href="./references#CD002217-bbs2-0019" title="CarlGF , SmithML . Phenytoin‐folate interactions: differing effects of the sodium salt and the free acid of phenytoin. Epilepsia1992;33(2):372‐5. ">Carl 1992</a>) and is associated with congenital abnormalities (<a href="./references#CD002217-bbs2-0023" title="GladstoneDJ , BologaM , MaguireC , PastuszakA , KorenG . Course of pregnancy and fetal outcome following maternal exposure to carbamazepine and phenytoin: a prospective study. Reproductive Toxicology1992;6(3):257‐61. ">Gladstone 1992</a>; <a href="./references#CD002217-bbs2-0042" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry2006;77(2):193‐8. ">Morrow 2006</a>; <a href="./references#CD002217-bbs2-0040" title="MeadorK , ReynoldsMW , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic review and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81(1):1‐13. ">Meador 2008</a>; <a href="./references#CD002217-bbs2-0054" title="NulmanI , ScolnikD , ChitayatD , FarkasLD , KorenG . Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. American Journal of Medical Genetics1997;68(1):18‐24. ">Nulman 1997</a>), particularly foetal hydantoin syndrome (<a href="./references#CD002217-bbs2-0062" title="ScheinfeldN . Phenytoin in cutaneous medicine: its uses, mechanisms and side effects. Dermatology Online Journal2003;9(3):6. ">Scheinfeld 2003</a>). Furthermore, due to the pharmacokinetic profile of phenytoin, the plasma concentrations are difficult to predict and dosing will usually need to be informed by measuring plasma concentration. </p> </section> <section id="CD002217-sec-0033"> <h3 class="title" id="CD002217-sec-0033">How the intervention might work</h3> <p>Antiepileptic drugs suppress seizures by reducing neuronal excitability (<a href="./references#CD002217-bbs2-0036" title="MacDonaldRL , KellyKM . Antiepileptic drug mechanisms of action. Epilepsia1995;36(Suppl 2):S2‐12. ">MacDonald 1995</a>). Phenobarbitone and carbamazepine are broad‐spectrum treatments suitable for many seizure types, and both have an anticonvulsant mechanism through blocking ion channels, binding with neurotransmitter receptors, or through inhibiting the metabolism or reuptake of neurotransmitters (<a href="./references#CD002217-bbs2-0057" title="RagsdaleDS , ScheuerT , CatterallWA . Frequency and voltage dependent inhibition of type hA Naı channels, expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology1991;40:756‐65. ">Ragsdale 1991</a>; <a href="./references#CD002217-bbs2-0071" title="WillowM , GonoiT , CatterallWA . Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage sensitive sodium channels in neuroblastoma cells. Molecular Pharmacology1985;27(5):549‐58. ">Willow 1985</a>), and the modulation of gamma‐aminobutyric acid‐A (GABA‐A), receptors (<a href="./references#CD002217-bbs2-0024" title="GrangerP , BitonB , FaureC , VigeX , DepoortereH , GrahamD , et al. Modulation of the gamma aminobutyricacid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology1995;47(6):1189‐96. ">Granger 1995</a>; <a href="./references#CD002217-bbs2-0058" title="RhoJM , DonevanSD , RogawskiMA . Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. Journal of Physiology1996;497(2):509‐22. ">Rho 1996</a>). </p> </section> <section id="CD002217-sec-0034"> <h3 class="title" id="CD002217-sec-0034">Why it is important to do this review</h3> <p>The aim of this review was to summarise efficacy and tolerability data from existing trials comparing phenobarbitone and phenytoin when used as monotherapy treatments. Although individual trials have found no consistent differences in efficacy, the confidence intervals generated by these trials are wide, and they have not excluded important differences in efficacy, which synthesising the data of the individual trials may show. </p> <p>There are difficulties in undertaking a systematic review of epilepsy monotherapy trials as the important efficacy outcomes require analysis of time‐to‐event data (for example, time to first seizure after randomisation). Although methods have been developed to synthesise time‐to‐event data using summary information (<a href="./references#CD002217-bbs2-0056" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD002217-bbs2-0070" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21:3337‐51. ">Williamson 2002</a>), the appropriate statistics are not commonly reported in published epilepsy trials (<a href="./references#CD002217-bbs2-0053" title="NolanSJ , SuttonL , MarsonA , Tudur SmithC . Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. Better knowledge for better health. 21st Cochrane Colloquium. Quebec City, Canada: The Cochrane Collaboration, 2013 September 19‐23:114‐5. ">Nolan 2013a</a>; <a href="./references#CD002217-bbs2-0069" title="WilliamsonPR , MarsonAG , TudurC , HuttonJL , ChadwickDW . Individual patient data meta‐analysis of randomized anti‐epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice2000;6(2):205‐14. ">Williamson 2000</a>). Furthermore, although most epilepsy monotherapy trials collect seizure data, there has been no uniformity in the definition and reporting of outcomes. For example, trials may report time to 12‐month remission but not time to first seizure or vice versa, or some trials may define time to first seizure from the date of randomisation while others use the date of achieving maintenance dose. Trial investigators have also adopted differing approaches to the analysis, particularly with respect to the censoring of time‐to‐event data. For these reasons, we performed this review using individual participant data (IPD), which helps to overcome these problems. This review is one in a series of Cochrane IPD reviews investigating pair‐wise monotherapy comparisons (<a href="./references#CD002217-bbs2-0039" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD002217-bbs2-0045" title="NevittSJ , MarsonAG , WestonJ , Tudur SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>; <a href="./references#CD002217-bbs2-0046" title="NevittSJ , Tudur SmithC , WestonJ , MarsonAG . Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4] ">Nevitt 2018a</a>; <a href="./references#CD002217-bbs2-0047" title="NevittSJ , MarsonAG , WestonJ , Tudur SmithC . Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD001769.pub4] ">Nevitt 2018b</a>; <a href="./references#CD002217-bbs2-0048" title="NevittSJ , Tudur SmithC , MarsonAG . Oxcarbazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD003615.pub4] ">Nevitt 2018c</a>; <a href="./references#CD002217-bbs2-0049" title="NevittSJ , MarsonAG , Tudur‐SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD001904.pub4] ">Nevitt 2018d</a>; <a href="./references#CD002217-bbs2-0050" title="NevittSJ , SudellM , Tudur SmithC , MarsonA . Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2019, Issue 6. [DOI: 10.1002/14651858.CD012065.pub3] ">Nevitt 2019a</a>). These data have also been included in IPD network meta‐analyses of antiepileptic drug monotherapy (<a href="./references#CD002217-bbs2-0044" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonAG . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>; <a href="./references#CD002217-bbs2-0065" title="Tudur SmithC , MarsonAG , ChadwickDW , WilliamsonPR . Multiple treatment comparisons in epilepsy monotherapy trials. Trials2007;5(8):34. ">Tudur Smith 2007</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD002217-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD002217-sec-0035"></div> <p>To review the time to treatment failure, remission and first seizure with phenobarbitone compared with phenytoin when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised), or generalised onset tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD002217-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD002217-sec-0036"></div> <section id="CD002217-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD002217-sec-0038"> <h4 class="title">Types of studies</h4> <p> <ul id="CD002217-list-0001"> <li> <p>Randomised controlled trials (RCTs) using either an adequate method of allocation concealment (e.g. sealed opaque envelopes) or a quasi‐randomised method of allocation (e.g. allocation by date of birth). </p> </li> <li> <p>Trials may have been double‐blind, single‐blind, or unblinded.</p> </li> <li> <p>Trials must be of parallel design; cross‐over studies are not an appropriate design for measuring the long‐term outcomes of interest in this review (see <a href="#CD002217-sec-0041">Types of outcome measures</a>). </p> </li> <li> <p>Trials must include a comparison of phenobarbitone monotherapy with phenytoin monotherapy in individuals with epilepsy; therefore, cluster randomised studies are not an eligible design. </p> </li> </ul> </p> </section> <section id="CD002217-sec-0039"> <h4 class="title">Types of participants</h4> <p> <ul id="CD002217-list-0002"> <li> <p>We included children or adults with focal onset seizures (simple focal, complex focal or secondarily generalised tonic‐clonic seizures), or generalised onset tonic‐clonic seizures, with or without other generalised seizure types (in other words, those who had only generalised tonic‐clonic seizures and those who had both generalised onset tonic‐clonic seizures and generalised seizures of other types (e.g. absence, myoclonic etc.)). </p> </li> <li> <p>We excluded individuals with other generalised seizure types alone without generalised tonic‐clonic seizures (e.g. those who had only absence seizures without any generalised clonic tonic‐seizures), due to differences in first‐line treatment guidelines for other generalised seizure types (<a href="./references#CD002217-bbs2-0052" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence. Clinical Guidance 137; available from: https://www.nice.org.uk/guidance/cg137/resources/epilepsies‐diagnosis‐and‐management‐35109515407813 (accessed 18 December 2018).2012. ">NICE 2012</a>). </p> </li> <li> <p>We included individuals who had a new diagnosis of epilepsy or who had experienced a relapse following antiepileptic monotherapy withdrawal only, due to differences in first‐line treatment guidelines for individuals with refractory epilepsy (<a href="./references#CD002217-bbs2-0052" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence. Clinical Guidance 137; available from: https://www.nice.org.uk/guidance/cg137/resources/epilepsies‐diagnosis‐and‐management‐35109515407813 (accessed 18 December 2018).2012. ">NICE 2012</a>). </p> </li> </ul> </p> </section> <section id="CD002217-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Phenobarbitone or phenytoin as monotherapy.</p> </section> <section id="CD002217-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Below is a list of outcomes we investigated in this review. Reporting of these outcomes in the original trial report was not an eligibility requirement for inclusion in this review. </p> <section id="CD002217-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Time to treatment failure (retention time). This was a combined outcome reflecting both efficacy and tolerability, as the following may have led to failure of treatment: continued seizures, side effects, non‐compliance or the initiation of additional add‐on treatment. This is an outcome to which the participant makes a contribution and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<a href="./references#CD002217-bbs2-0029" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799. ">ILAE 1998</a>; <a href="./references#CD002217-bbs2-0030" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: evidence‐based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). </p> <p>Time to treatment failure is considered according to three definitions.</p> <p> <ul id="CD002217-list-0003"> <li> <p>Time to treatment failure for any treatment‐related reason (continued seizures, side effects, non‐compliance or the initiation of additional add‐on treatment) </p> </li> <li> <p>Time to treatment failure due to adverse events (i.e. side effects)</p> </li> <li> <p>Time to treatment failure due to lack of efficacy (i.e. continued seizures)</p> </li> </ul> </p> </section> <section id="CD002217-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD002217-list-0004"> <li> <p>Time to first seizure post‐randomisation</p> </li> <li> <p>Time to achieve 12‐month remission (seizure‐free period)</p> </li> <li> <p>Time to achieve six‐month remission (seizure‐free period)</p> </li> </ul> </p> </section> </section> </section> <section id="CD002217-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD002217-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The first searches for this review were run in 2001. Subsequent searches were run in December 2006, October 2009, May 2012, and July 2014. For the most recent update we searched the following databases on 21 August 2018. There were no language restrictions. </p> <p> <ul id="CD002217-list-0005"> <li> <p>The Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), using the strategy outlined in <a href="./appendices#CD002217-sec-0110">Appendix 1</a>. </p> </li> <li> <p>MEDLINE (Ovid, 1946 to August 20, 2018) using the strategy outlined in <a href="./appendices#CD002217-sec-0111">Appendix 2</a>. </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> using the strategy outlined in <a href="./appendices#CD002217-sec-0112">Appendix 3</a>. </p> </li> <li> <p>The World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">ICTRP</a>) using the strategy outlined in <a href="./appendices#CD002217-sec-0113">Appendix 4</a>. </p> </li> </ul> </p> </section> <section id="CD002217-sec-0046"> <h4 class="title">Searching other resources</h4> <p>In addition, we handsearched relevant journals, and contacted pharmaceutical companies and researchers in the field to seek any ongoing or unpublished studies. </p> </section> </section> <section id="CD002217-sec-0047"> <h3 class="title" id="CD002217-sec-0047">Data collection and analysis</h3> <section id="CD002217-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SJN and AGM) independently assessed trials for inclusion. Any disagreements were resolved my mutual discussion. </p> </section> <section id="CD002217-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We requested the following IPD for all trials meeting our inclusion criteria.</p> <section id="CD002217-sec-0050"> <h5 class="title">Trial methods</h5> <p> <ul id="CD002217-list-0006"> <li> <p>Method of generation of random list</p> </li> <li> <p>Method of concealment of randomisation</p> </li> <li> <p>Stratification factors</p> </li> <li> <p>Blinding methods</p> </li> </ul> </p> </section> <section id="CD002217-sec-0051"> <h5 class="title">Participant covariates</h5> <p> <ul id="CD002217-list-0007"> <li> <p>Gender</p> </li> <li> <p>Age</p> </li> <li> <p>Seizure types</p> </li> <li> <p>Time between first seizure and randomisation</p> </li> <li> <p>Number of seizures prior to randomisation (with dates)</p> </li> <li> <p>Presence of neurological signs</p> </li> <li> <p>Electroencephalographic (EEG), results</p> </li> <li> <p>Computerised tomography/magnetic resonance imaging (CT/MRI), results</p> </li> </ul> </p> </section> <section id="CD002217-sec-0052"> <h5 class="title">Follow‐up data</h5> <p> <ul id="CD002217-list-0008"> <li> <p>Treatment allocation</p> </li> <li> <p>Date of randomisation</p> </li> <li> <p>Dates of follow‐up</p> </li> <li> <p>Dates of seizures post‐randomisation or seizure frequency data between follow‐up visits</p> </li> <li> <p>Dates of treatment failure and reasons for treatment failure</p> </li> <li> <p>Dose</p> </li> <li> <p>Dates of dose changes</p> </li> </ul> </p> <p>For each trial for which we did not obtain IPD, we carried out an assessment to see whether any relevant aggregate‐level data have been reported or could be indirectly estimated using the methods of <a href="./references#CD002217-bbs2-0056" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a> and <a href="./references#CD002217-bbs2-0070" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21:3337‐51. ">Williamson 2002</a>. </p> <p>Two trials involving 414 participants, provided seizure data in terms of the number of seizures recorded between each follow‐up visit rather than specific dates of seizures (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). To enable the calculation of time‐to‐event outcomes, we applied linear interpolation to approximate dates of seizures between follow‐up visits. For example, if the trial recorded four seizures between two visits that occurred on 1 March 1990 and 1 May 1990 (interval of 61 days), then the date of first seizure would be approximately 13 March 1990. This allowed the computation of an estimate of the time to six‐month remission, 12‐month remission, and first seizure. </p> <p>We calculated time to six‐month and 12‐month remission from the date of randomisation to the date (or estimated date), that the individual had first been free of seizures for six or 12 months, respectively. If the person had one or more seizures in the titration period, a six‐month or 12‐month seizure‐free period could also occur between the estimated date of the last seizure in the titration period and the estimated date of the first seizure in the maintenance period. </p> <p>We calculated time to first seizure from the date of randomisation to the date that we estimated their first seizure to have occurred. If seizure data were missing for a particular visit, we censored these outcomes at the previous visit. We also censored these outcomes if the individual died or if follow‐up ceased prior to the occurrence of the event of interest. We used these methods in the remaining three trials involving 221 participants (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>), for which we directly received outcome data (dates of seizures after randomisation). </p> <p>In the <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> trial, all 36 participants completed the 12‐week trial duration and no participants withdrew from the trial or from the allocated treatment and no treatment failure data were available for <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>. For the remaining three trials (505 participants), we extracted dates and reason for treatment failure or withdrawal from trial case report forms for the original review (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>). </p> <p>Two review authors (SJN and AGM) independently extracted data from all case report forms, resolving disagreements by reconsidering the case report forms at conference. For the analysis of time‐to‐event data, we defined an 'event' as either the failure of the allocated treatment because of poor seizure control, adverse events, or both. We also classed non‐compliance with the treatment regimen or the addition of another antiepileptic drug as 'events' for the outcome 'time to treatment failure.' We censored the outcome if treatment was stopped because the individual achieved a period of remission or if the individual was still on allocated treatment at the end of follow‐up. </p> </section> </section> <section id="CD002217-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SJN and CTS), independently assessed all included trials for risk of bias according to the Cochrane 'Risk of bias' tool (<a href="./references#CD002217-bbs2-0027" title="HigginsJP , AltmanDG , Sterne JA(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017, Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), resolving any disagreements by discussion. We rated each of the following six domains as low, unclear or high risk of bias: method of generating random sequence, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. Any discrepancies in the two authors' 'Risk of bias' judgements were resolved by discussion. </p> </section> <section id="CD002217-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>We measured all outcomes in this review as time‐to‐event outcomes with the hazard ratio (HR), and 95% confidence interval (CI), used as the measure of treatment effect. We calculated outcomes from IPD provided, where possible, or extracted from published trials if possible. </p> </section> <section id="CD002217-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>We did not have any unit of analysis issues. The unit of allocation and analysis was individual for all included trials, and no trials included in meta‐analysis were of a repeated measures (longitudinal), nature or of a cross‐over design. </p> </section> <section id="CD002217-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>For each trial that supplied IPD, we reproduced results from trial results where possible and performed consistency checks. </p> <p> <ul id="CD002217-list-0009"> <li> <p>We cross‐checked trial details against any published report of the trial and contacted original trial authors if we found missing data, errors, or inconsistencies. </p> </li> <li> <p>If trial authors could not resolve inconsistencies between IPD and published data, depending on the extent of the inconsistencies, we performed sensitivity analysis (see <a href="#CD002217-sec-0061">Sensitivity analysis</a>), or excluded the data from the meta‐analysis. </p> </li> <li> <p>We reviewed the chronological randomisation sequence and checked the balance of prognostic factors, taking account of factors stratified for in the randomisation procedure. </p> </li> </ul> </p> </section> <section id="CD002217-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity statistically using the Q test (P &lt; 0.10 for significance), and the I² statistic (greater than 50% indicating considerable heterogeneity; <a href="./references#CD002217-bbs2-0026" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>), output produced using the generic inverse variance approach in <a href="./references#CD002217-sec-0108" title="">Data and analyses</a>, and visually by inspecting forest plots. </p> </section> <section id="CD002217-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>Two review authors (SJN and CTS), undertook all full quality and 'Risk of bias' assessments. In theory, a review using IPD should overcome issues of reporting biases, as unpublished data can be provided and unpublished outcomes calculated. Any selective reporting bias detected could be assessed with the Outcome Reporting Bias In Trials (ORBIT), classification system (<a href="./references#CD002217-bbs2-0033" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). </p> </section> <section id="CD002217-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We carried out our analysis on an intention‐to‐treat basis (that is, we analysed participants in the group to which they were randomised, irrespective of which treatment they actually received). Therefore, for the time‐to‐event outcomes 'time to six‐month remission', 'time to 12‐month remission', and 'time to first seizure post‐randomisation', we did not censor participants if treatment was withdrawn or failed. </p> <p>For all outcomes, we investigated the relationship between the time‐to‐event and treatment effect of the antiepileptic drugs. We used Cox proportional hazards regression models to obtain trial‐specific estimates of log (HR), or treatment effect and associated standard errors in Stata Statistical Software, version 14 (<a href="https://archie.cochrane.org/sections/documents/view?version=z1810161445427693100361160184097%26format=REVMAN#REF-Stata-2015" target="_blank">Stata 2015</a>). The model assumes that the ratio of hazards (risks), between the two treatment groups is constant over time (i.e. hazards are proportional). We tested this proportional hazards assumption of the Cox regression model for each outcome of each trial by testing the statistical significance of a time‐varying covariate in the model. We evaluated overall estimates of HRs (with 95% confidence intervals (CIs)), using the generic inverse variance method. We expressed results as anHR and a 95% CI. </p> <p>By convention, an HR greater than 1 indicates that an event is more likely to occur earlier on phenobarbitone than on phenytoin. Hence, for time to treatment failure or time to first seizure, an HR greater than 1 indicates a clinical advantage for phenytoin (e.g. an HR of 1.2 would suggest a 20% increase in risk of treatment failure from phenobarbitone compared to phenytoin), and for time to six‐month and 12‐month remission, an HR greater than 1 indicates a clinical advantage for phenytoin. </p> </section> <section id="CD002217-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>To examine the potential impact of seizure type on results, we stratified all analyses by seizure type (focal onset versus generalised onset), according to the classification of main seizure type at baseline. We classified focal seizures (simple or complex), and focal secondarily generalised seizures as focal epilepsy. </p> <p>We classified primarily generalised seizures as generalised epilepsy. We conducted a Chi² test of interaction between treatment and seizure type. If we found significant statistical heterogeneity to be present, we performed meta‐analysis with a random‐effects model in addition to a fixed‐effect model, presenting the results of both models and performing sensitivity analyses to investigate differences in trial characteristics. </p> </section> <section id="CD002217-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We performed several sensitivity analyses to test the robustness of our results to characteristics of the included trials. </p> <p> <ul id="CD002217-list-0010"> <li> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> withdrew the phenobarbitone arm of the trial after 10 children were randomised to phenobarbitone due to concerns over unacceptable side effects. The trial did not randomise any further children to phenobarbitone and continued with the three other treatment arms: carbamazepine, phenytoin, and sodium valproate. For the primary and secondary outcomes of this review, we included all children randomised to phenytoin (n = 54), and phenobarbitone (n = 10), from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, and to account for the imbalance between children randomised to the two drugs on this trial, we performed sensitivity analysis including only those children who were randomised before the withdrawal of the phenobarbitone arm from the trial. For sensitivity analysis, we analysed 19 children (11 boys and eight girls), 10 randomised to phenobarbitone and nine randomised to phenytoin, 11 with generalised seizures and eight with focal seizures. We performed this sensitivity analysis for each outcome and observed any change to results and conclusions. </p> </li> <li> <p>Misclassification of seizure type is a recognised problem in epilepsy, whereby some people with generalised seizures have been mistakenly classed as having focal onset seizures and vice versa. There is clinical evidence that individuals with generalised onset seizures are unlikely to have an 'age of onset' greater than 25 to 30 years (<a href="./references#CD002217-bbs2-0038" title="MalfosseA , GentonP , HirschE , MarescauxC , BroglinD , BernasconiR . Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994. ">Malafosse 1994</a>). Such misclassification affected the results of three reviews in our series of pair‐wise reviews for monotherapy in epilepsy comparing carbamazepine to phenobarbitone, phenytoin and sodium valproate in which around 30% to 50% of participants analysed may have had their seizure type misclassified as generalised onset (<a href="./references#CD002217-bbs2-0039" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD002217-bbs2-0045" title="NevittSJ , MarsonAG , WestonJ , Tudur SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>; <a href="./references#CD002217-bbs2-0047" title="NevittSJ , MarsonAG , WestonJ , Tudur SmithC . Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 8. [DOI: 10.1002/14651858.CD001769.pub4] ">Nevitt 2018b</a>). Given the potential biases introduced into those reviews, we examined the distribution of age at onset for individuals with generalised seizures in the trials included in this review, to assess the potential impact of misclassification of seizure type on the outcomes. </p> <ul id="CD002217-list-0011"> <li> <p>33 out of 68 individuals (49%), with generalised onset seizures were over the age of 30 in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>, </p> </li> <li> <p>13 out of 31 individuals (42%), with generalised onset seizures were over the age of 30 in <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> </p> </li> </ul> </li> </ul> </p> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> and <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> were paediatric trials, and <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> recruited participants with focal seizures only, so there were no participants with new onset generalised seizures over the age of 30 in these trials. Therefore, out of 162 participants classified as experiencing generalised seizures from the five trials providing IPD, 46 (28%), may have been wrongly classified. </p> <p>To investigate misclassification for each outcome, we undertook the following two analyses to investigate misclassification. </p> <p> <ul id="CD002217-list-0012"> <li> <p>We reclassified all individuals with generalised seizures and age at onset greater than 30 into an 'uncertain seizure type' group. </p> </li> <li> <p>We reclassified individuals with generalised seizures and age at onset greater than 30 as having focal onset seizures. </p> </li> </ul> </p> <section id="CD002217-sec-0062"> <h5 class="title">'Summary of findings' tables and certainty of the evidence (GRADE)</h5> <p>For this 2019 update, we added two 'Summary of findings' tables to the review (outcomes in the tables decided before the update started based on clinical relevance). </p> <p><a href="./full#CD002217-tbl-0001">summary of findings Table for the main comparison</a> reports the primary outcome of 'time to treatment failure' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by seizure type. </p> <p><a href="./full#CD002217-tbl-0002">summary of findings Table 2</a> reports the secondary outcomes of 'time to first seizure' and 'time to 12‐month remission' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by seizure type. </p> <p>We determined the quality of the evidence using the GRADE approach, where we downgraded evidence in the presence of high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results and high probability of publication bias. We downgraded evidence by one level if we considered the limitation serious and two levels for very serious. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD002217-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD002217-sec-0063"></div> <section id="CD002217-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD002217-sec-0065"> <h4 class="title">Results of the search</h4> <p>In previous versions of the review (<a href="./references#CD002217-bbs2-0072" title="NolanSJ , Tudur SmithC , PulmanJ , MarsonAG . Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2] ">Nolan 2013b</a>, <a href="./references#CD002217-bbs2-0074" title="TaylorS , Tudur SmithC , WilliamsonPR , MarsonAG . Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2001, Issue 4. [DOI: 10.1002/14651858.CD002217] ">Taylor 2001</a>), eight studies were included (<a href="./references#CD002217-bbs2-0009" title="CereghinoJJ , BrockJT , VanMeterJC , PenryJK , SmithLD , WhiteBG . Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology1974;24(5):401‐10. ">Cereghino 1974</a>; <a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0011" title="GruberCM , BrockJT . Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital and methylphenylhydantoin in motor seizures. Clinical Pharmacology and Therapeutics1962;3(1):23‐8. ">Gruber 1962</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>) and five studies were listed as excluded (<a href="./references#CD002217-bbs2-0008" title="BirdCA , GriffinBP , MiklaszewkaJM , GalbraithAW . Tegretol (carbamazepine): a controlled trial of a new anti‐convulsant. British Journal of Psychiatry1966;112:737‐42. ">Bird 1966</a>; <a href="./references#CD002217-bbs2-0010" title="CereghinoJJ , BrockJT , VanMeterJC , PenryJK , SmithLD , WhiteBG . The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology and Therapeutics1975;18(6):733‐41. ">Cereghino 1975</a>; <a href="./references#CD002217-bbs2-0012" title="MeadorK , LoringD , HuhK , GallagherB , KingD . Comparative cognitive effects of anticonvulsants. Neurology1990;40(3 Pt 1):391‐4. ">Meador 1990</a>; <a href="./references#CD002217-bbs2-0013" title="VermaG , PathakU , JaiswalV , UpadhyayA . Comparision of phenobarbitone with phenytoin for the treatment of seizures in term and near term neonates. Pediatric Academic Societies Annual Meeting, 1‐4 May 2010, Vancouver. Abstract No: 2849.304. http://www.abstracts2view.com/pasall/view.php?nu=PAS10L1_17062010. ">Verma 2010</a>; <a href="./references#CD002217-bbs2-0014" title="WhiteTW , PlottD , NortonJ . Relative anticonvulsant potency of primidone. Archives of Neurology1966;14(1):31‐5. ">White 1966</a>). In this update of the review, we have updated the inclusion and exclusion criteria of the review and cross‐over design studies have been excluded as this design is not appropriate for measuring the long‐term outcomes of the review. Therefore two previously included cross‐over studies now excluded from the review (<a href="./references#CD002217-bbs2-0009" title="CereghinoJJ , BrockJT , VanMeterJC , PenryJK , SmithLD , WhiteBG . Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology1974;24(5):401‐10. ">Cereghino 1974</a>; <a href="./references#CD002217-bbs2-0011" title="GruberCM , BrockJT . Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital and methylphenylhydantoin in motor seizures. Clinical Pharmacology and Therapeutics1962;3(1):23‐8. ">Gruber 1962</a>). </p> <p>For this update, from electronic searches conducted in July 2014 and August 2018, we identified 75 records from the databases and search strategies outlined in <a href="#CD002217-sec-0045">Electronic searches</a>. We found one further record by searching other resources (an included study within another Cochrane Review (<a href="./references#CD002217-bbs2-0044" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonAG . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>)). We removed six duplicate records and screened 69 records (title and abstract), for inclusion in the review. We excluded 69 records based on the title and abstract and assessed one full‐text articles for inclusion in the review. We excluded seven trials (see <a href="#CD002217-sec-0067">Excluded studies</a> below), and included seven trials in the review (see <a href="./references#CD002217-bbs1-0001" title="">Included studies</a>). See <a href="#CD002217-fig-0001">Figure 1</a> for a PRISMA study flow diagram (<a href="./references#CD002217-bbs2-0041" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: the PRISMA Statement. BMJ2009;339:b2535. ">Moher 2009</a>). </p> <div class="figure" id="CD002217-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD002217-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD002217-sec-0066"> <h4 class="title">Included studies</h4> <p>Seven studies were identified as eligible for this systematic review (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>) </p> <p>Four of the studies recruited adults (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>) and three recruited children (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). Four studies recruited individuals with focal onset and generalised onset seizures (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>), two recruited individuals with focal onset seizures only (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>), one recruited individuals with generalised onset seizures only (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). Six trials recruited individuals with new onset seizures, or previously untreated seizures, or both (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>) one trial recruited "previously untreated or under‐treated" individuals (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) </p> <p>Three studies were conducted in Europe (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>), two studies were conducted in India (<a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>), one study was conducted in the USA (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>), and one study was conducted in Nigeria (<a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>). </p> <p>Individual participant data (IPD) were obtained for five studies, which recruited a total of 635 participants, representing 80% of 798 individuals from all seven identified eligible trials. For three trials, computerised data were directly provided (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>), and the authors of two trials (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>) supplied a combination of both computerised and hard copy data (although mostly computerised). </p> <p>Data were available for the following participant characteristics (percentage of 635 participants with data available): epilepsy type (100%), age at randomisation (99%, data missing for two participants from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>), sex (99%, data missing for two participants from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and two participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>); drug randomised (99%, data missing for six participants in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>), time since first seizure to randomisation (94%, data missing for all 36 participants from <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, two participants from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>, two participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, and one participant from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>); number of seizures in six months prior to randomisation (85%, data missing for all 94 participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and for three participants from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>). See the <a href="./references#CD002217-sec-0124" title="">Characteristics of included studies</a> and <a href="#CD002217-tbl-0003">Table 1</a> for further details. </p> <div class="table" id="CD002217-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Male participants:<br/> n (%)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Age at entry (years): Mean (SD), range<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Epilepsy duration<br/> (years): mean (SD),<br/> range<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number of seizures</b> </p> <p><b>in prior 6 months, median (range)<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 (3.9)</p> <p>(4 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (3.4)</p> <p>(3 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (1.8)</p> <p>(0 to 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 (2.1)</p> <p>(0 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 404)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5 (15.1)</p> <p>(26 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.5 (14.3)</p> <p>(14 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (6.6)</p> <p>(0 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (5.4)</p> <p>(0 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 579)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> <p>(1 to 575)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.1 (15.3)</p> <p>(18 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8 (15.3)</p> <p>(18 to 81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7 (7.9)</p> <p>(0.5 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6 (9.1)</p> <p>(0.5 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> <p>(1 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> <p>(1 to 26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> <p>(61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.4 (6.2)</p> <p>(26 to 55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.8 (2.6)</p> <p>(15 to 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> <p>(6 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> <p>(6 to 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (55%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5 (4.8)</p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3 (5.2)</p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (3.8)</p> <p>(0.5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 (4.3)</p> <p>0.5 to 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n: number of participants; NA: not available; PB: phenobarbitone; PHT:phenytoin SD: standard deviation </p> <p>a. Sex was missing for four participants, two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and two participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> (one on PB and one on PHT). Proportions (%) are calculated based on non‐missing data. </p> <p>b. Age at randomisation was missing for two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> <p>c. Epilepsy duration was missing for 41 participants; all 36 participants from <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>, one participant on PB from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and two participants on PHT from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> <p>d. Number of seizures in the prior six months was missing for 97 participants, all 94 participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and three participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> <p>e. Randomised drug missing for 6 participants in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>. </p> </div> </div> <p>Four trials provided the results of neurological examinations for 315 participants (50% of total participants with IPD provided; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). All participants had a normal neurological examination in <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, 91% of participants in both <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> and <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> had a normal neurological examination. However, in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, 74% of participants were reported to have an abnormal neurological examination. </p> <p>Electroencephalographic (EEG) and computerised tomography (CT) data were provided for 307 and 273 participants respectively from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; 71% of participants with EEG data had an abnormal EEG and 27% of participant with CT data had an abnormal scan. <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> reported that none of the 36 participants had an abnormal scan. EEG and CT data were not available for the other three studies (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). </p> <p>The largest study (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) contributing 320 participants (50% of total IPD provided) recruited participants with focal onset seizures only, therefore, of the 635 participants analysed, only 167 (26%) had generalised onset seizures. </p> <p>We did not obtain IPD for the remaining two studies, with a total of 163 participants (20% of total eligible data), as we were not able to make contact with original trial authors to request data (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>), or authors did not provide IPD, despite responding positively to our requests (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>). Neither of these trials reported the specific time‐to‐event outcomes chosen for this review, and we could not extract sufficient aggregate data from the trial publications in any other trial. Therefore, we could not include them in data synthesis. <a href="#CD002217-tbl-0004">Table 2</a> contains full details of outcomes considered and summaries of results in each eligible trial for which IPD were not available. </p> <div class="table" id="CD002217-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes considered and summary of results for trials with no IPD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes Reported</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Summary of Results </b> </p> <p><b> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Proportion achieving 24‐month remission at 3 years</p> <p>2. Proportion "excluded" after randomisation due to adverse effects or no efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. PB: 60% PHT: 59%</p> <p>2. PB: 33% PHT: 23%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Recurrence of Seizures</p> <p>2. Side Effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. PB:16 out of 51 participants (31%) PHT: 14 out of 52 participants (27%)</p> <p>2. PB:17 out of 51 participants (33%) PHT: 33 out of 52 participants (63%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>IPD: individual participant data, PB: phenobarbitone, PHT: phenytoin</p> </div> </div> </section> <section id="CD002217-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded seven studies from this review. Two studies made polytherapy comparisons (<a href="./references#CD002217-bbs2-0010" title="CereghinoJJ , BrockJT , VanMeterJC , PenryJK , SmithLD , WhiteBG . The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology and Therapeutics1975;18(6):733‐41. ">Cereghino 1975</a>; <a href="./references#CD002217-bbs2-0014" title="WhiteTW , PlottD , NortonJ . Relative anticonvulsant potency of primidone. Archives of Neurology1966;14(1):31‐5. ">White 1966</a>), or it was unclear if a monotherapy comparison was made in the study (<a href="./references#CD002217-bbs2-0008" title="BirdCA , GriffinBP , MiklaszewkaJM , GalbraithAW . Tegretol (carbamazepine): a controlled trial of a new anti‐convulsant. British Journal of Psychiatry1966;112:737‐42. ">Bird 1966</a>; <a href="./references#CD002217-bbs2-0012" title="MeadorK , LoringD , HuhK , GallagherB , KingD . Comparative cognitive effects of anticonvulsants. Neurology1990;40(3 Pt 1):391‐4. ">Meador 1990</a>). Two studies were cross‐over studies (<a href="./references#CD002217-bbs2-0009" title="CereghinoJJ , BrockJT , VanMeterJC , PenryJK , SmithLD , WhiteBG . Carbamazepine for epilepsy: a controlled prospective evaluation. Neurology1974;24(5):401‐10. ">Cereghino 1974</a>; <a href="./references#CD002217-bbs2-0011" title="GruberCM , BrockJT . Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital and methylphenylhydantoin in motor seizures. Clinical Pharmacology and Therapeutics1962;3(1):23‐8. ">Gruber 1962</a>), a design which is not appropriate for measuring the long‐term outcomes in this review and one study recruited participants with neonatal seizures due to birth asphyxia, rather than epileptic seizures (<a href="./references#CD002217-bbs2-0013" title="VermaG , PathakU , JaiswalV , UpadhyayA . Comparision of phenobarbitone with phenytoin for the treatment of seizures in term and near term neonates. Pediatric Academic Societies Annual Meeting, 1‐4 May 2010, Vancouver. Abstract No: 2849.304. http://www.abstracts2view.com/pasall/view.php?nu=PAS10L1_17062010. ">Verma 2010</a>). See <a href="./references#CD002217-sec-0125" title="">Characteristics of excluded studies</a> tables for further details. </p> </section> </section> <section id="CD002217-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>For further details see <a href="./references#CD002217-sec-0124" title="">Characteristics of included studies</a>, <a href="#CD002217-fig-0002">Figure 2</a> and <a href="#CD002217-fig-0003">Figure 3</a> </p> <div class="figure" id="CD002217-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002217-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD002217-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002217-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD002217-sec-0069"> <h4 class="title">Allocation</h4> <section id="CD002217-sec-0070"> <h5 class="title">Trials for which we received IPD</h5> <p>Two of the trials randomised participants via a random list generated from random permuted blocks and used sealed opaque envelopes as the method of concealment of randomisation; these trials were judged to be at low risk of selection bias (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>). One trial used simple randomisation from a random number table with allocation of treatments taking place at a different site and was also judged to be at low risk of selection bias (<a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>). </p> <p>One trial randomised participants with a prepared random number list and by minimisation (low risk of bias) but did not provide any information regarding allocation concealment (unclear risk of bias) (<a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). The final trial did not state the method of randomisation or allocation concealment used and was judged to be at unclear risk of selection bias (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>). </p> </section> <section id="CD002217-sec-0071"> <h5 class="title">Trials for which no IPD were available</h5> <p>One trial randomised participants using computer‐generated random numbers and was judged to be at low risk of bias (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>), while <a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a> was judged to be at unclear risk of bias as the trial was described as 'randomised' but no details of the randomisation method were provided. The method of allocation concealment was not stated either of the studies so both studies were judged to be at unclear risk of bias. </p> </section> </section> <section id="CD002217-sec-0072"> <h4 class="title">Blinding</h4> <section id="CD002217-sec-0073"> <h5 class="title">Trials for which we received IPD</h5> <p>Two trials were completely unblinded for quote: "practical and ethical reasons" and were judged to be at high risk of performance bias and detection bias (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>). One trial did not blind participants and personnel for quote: "practical and ethical reasons" but single blinded for outcome (<a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>); we judged this trial to be at high risk of performance bias but low risk of detection bias. </p> <p>One trial was double‐blinded (participants and personnel), achieved using an additional placebo tablet (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) and one trial blinded participants (placebo tablet) and outcome assessors (<a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>); both trials were judged to be at low risk of performance bias and detection bias. </p> </section> <section id="CD002217-sec-0074"> <h5 class="title">Trials for which no IPD were available</h5> <p>One trial was double‐blinded (participants and personnel), achieved using additional blank tablets and was judged to be at low risk of bias (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). Blinding was not mentioned in <a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a> so we judged this study to be at unclear risk of bias. </p> </section> </section> <section id="CD002217-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <section id="CD002217-sec-0076"> <h5 class="title">Trials for which we received IPD</h5> <p>In theory, a review using IPD should overcome issues of attrition bias as unpublished data can be provided, unpublished outcomes calculated, and all randomised participants can be analysed by an intention‐to‐treat approach. All five trials provided IPD for all randomised individuals and reported the extent of follow‐up for each individual; we judged all five trials to be at low risk of attrition bias (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). We queried any missing data with the original trial authors. From the information provided by the trial authors, we deemed the small amount of missing data present (see <a href="#CD002217-sec-0066">Included studies</a>), to be missing at random and not affecting our analysis. </p> </section> <section id="CD002217-sec-0077"> <h5 class="title">Trials for which no IPD were available</h5> <p>One trial reported attrition rates and analysed all randomised participants using an intention‐to‐treat approach so was judged to be at low risk of bias (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). The other trial reported attrition rates, but it was unclear if all participants were analysed (by an intention‐to‐treat approach or otherwise), therefore this trial was judged to be at unclear risk of attrition bias (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>). </p> </section> </section> <section id="CD002217-sec-0078"> <h4 class="title">Selective reporting</h4> <p>We requested trial protocols in all IPD requests; however, protocols were not available for any of the seven trials included in the review, so we made a judgement of the risk of bias based on the information included in the publications or from the IPD we received (see the '<a href="./references#CD002217-sec-0124" title="">Characteristics of included studies</a>' tables for more information). </p> <section id="CD002217-sec-0079"> <h5 class="title">Trials for which we received IPD</h5> <p>Trials for which we received IPD In theory, a review using IPD should overcome issues of reporting biases as unpublished data can be provided and unpublished outcomes calculated so all trials providing IPD were judged to be at low risk of reporting bias. We received sufficient IPD to calculate the four outcomes ('time to treatment failure', 'time to six‐month remission, 'time to 12‐month remission', and 'time to first seizure'), for three of the six trials (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>). The trial duration of <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> was 12 weeks, and all randomised participants completed the trial; therefore, we could only calculate 'time to first seizure' for this trial. Treatment failure data were not available for <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>. </p> </section> <section id="CD002217-sec-0080"> <h5 class="title">Trials for which no IPD were available</h5> <p>One trial reported seizure reduction and adverse event outcomes well and therefore was judged to be at low risk of reporting bias (<a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). The other trial was available in abstract form only (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>) and did not provide sufficient information to assess selective reporting bias (unclear risk of reporting bias). </p> </section> </section> <section id="CD002217-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>No other sources of bias were identified in six of the seven studies (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>). One trial which was available in abstract form only (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>) reported very limited methodological information therefore it is unclear if there were any other potential sources of bias. </p> </section> </section> <section id="CD002217-sec-0082"> <h3 class="title" id="CD002217-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD002217-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</a>; <a href="./full#CD002217-tbl-0002"><b>Summary of findings 2</b> Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</a> </p> <p>We have provided a summary of the outcomes reported in trials for which no IPD were available in <a href="#CD002217-tbl-0004">Table 2</a>. </p> <p>See <a href="#CD002217-tbl-0005">Table 3</a> for details regarding the number of individuals contributing IPD to each analysis, <a href="./full#CD002217-tbl-0001">summary of findings Table for the main comparison</a> for a summary of the results for the primary outcome 'time to treatment failure' (stratified by seizure type), and <a href="./full#CD002217-tbl-0002">summary of findings Table 2</a> for a summary of results for the secondary outcomes 'time to first seizure' and 'time to 12‐month remission'. </p> <div class="table" id="CD002217-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants contributing to analysis ‐ by epilepsy type</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Epilepsy Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to 6‐month and</b> </p> <p><b>12‐month remission<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to 1st seizure<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to treatment failure</b> </p> <p><b>(any reason, adverse events</b> </p> <p><b> or lack of efficacy)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>279</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PB: phenobarbitone, PHT: phenytoin</p> <p>a. Seizure data after randomisation was not available for seven participants (four on PB and three on PHT) in <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and for four participants (three on PB and one on PHT) in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>. Therefore time to first seizure after randomisation and time to 6‐month and 12‐month remission could not be calculated for these outcomes. </p> <p>b. For <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> information on time to treatment failure is not available. In <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, all 36 participants completed the 12‐week trial duration and no participants withdrew from the trial or from the allocated treatment, therefore only time to first seizure after randomisation could be calculated for this trial. </p> </div> </div> <p>Survival curve plots are shown in <a href="#CD002217-fig-0004">Figure 4</a>; <a href="#CD002217-fig-0005">Figure 5</a>; <a href="#CD002217-fig-0006">Figure 6</a>; <a href="#CD002217-fig-0007">Figure 7</a>; <a href="#CD002217-fig-0008">Figure 8</a>; <a href="#CD002217-fig-0009">Figure 9</a>; <a href="#CD002217-fig-0010">Figure 10</a>; <a href="#CD002217-fig-0011">Figure 11</a>; <a href="#CD002217-fig-0012">Figure 12</a>; <a href="#CD002217-fig-0013">Figure 13</a>; <a href="#CD002217-fig-0014">Figure 14</a> and <a href="#CD002217-fig-0015">Figure 15</a> . </p> <div class="figure" id="CD002217-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Time to treatment failure ‐ any reason related to the treatment (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> </div> <div class="figure" id="CD002217-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> </div> <div class="figure" id="CD002217-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Time to treatment failure due to adverse events (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to adverse events (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Time to treatment failure due to adverse events, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to adverse events, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> </div> <div class="figure" id="CD002217-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Time to treatment failure due to lack of efficacy (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Time to treatment failure due to lack of efficacy, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> </div> <div class="figure" id="CD002217-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Time to first seizure (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Time to first seizure, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Time to 12 month remission (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 12 month remission (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Time to 12 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 12 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0014"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 14</div> </div> <hr class="top"/><img alt="Time to 6 month remission (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 6 month remission (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <div class="figure" id="CD002217-fig-0015"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 15</div> </div> <hr class="top"/><img alt="Time to 6 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG15.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 6 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> </div> <p>We used Stata software version 14 to produce all survival curve plots using data from all trials providing IPD combined (<a href="./references#CD002217-bbs2-0063" title="StataCorp . Stata Statistical Software: Release 14. College Station, TX: StataCorp LP, 2015. ">Stata 2015</a>). We note that participants with event times of zero (i.e. those who experienced treatment failure or experienced seizure recurrence on the day of randomisation), are not included in the 'Numbers at risk' on the graphs and that data are not stratified by trial within these survival curve plots. All figures are intended to provide a visual representation of outcomes, extent of follow‐up and visual differences between seizure types. These graphs are not intended to show statistical significance and numerical values may vary compared to the text due to differences in methodology. </p> <p>We calculated all hazard ratios (HRs), presented below by fixed‐effect generic inverse variance meta‐analysis unless otherwise stated. All analyses met the assumption of proportional hazards (addition of time‐varying covariate into the model non‐significant), unless otherwise stated. </p> <section id="CD002217-sec-0083"> <h4 class="title">Primary outcome</h4> <section id="CD002217-sec-0084"> <h5 class="title">Time to treatment failure (retention time)</h5> <p>For this outcome, an HR of less than one indicates a clinical advantage for phenobarbitone.</p> <p>Times to treatment failure and reasons for treatment failure were available for 499 participants from three of the five trials providing IPD (78.6% of 635 participants from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and 62.4% of the total 798 participants from the seven included trials). See <a href="#CD002217-tbl-0006">Table 4</a> for reasons for premature discontinuation of treatment (treatment failure), by treatment and how we classified these reasons in analysis. </p> <div class="table" id="CD002217-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reason for early termination</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a><b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a><b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. "><b>Mattson 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both adverse events and lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐compliance/protocol violation (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Illness or death (not treatment‐related, censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant went into remission (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lost to follow‐up (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (censored)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completed the trial (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>55</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>220</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>281</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>501</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>PB: phenobarbitone, PHT: phenytoin<br/> <br/> a. One participant on PHT in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> has a missing treatment failure time and reason and did not contribute to analysis </p> <p>b. Five participants from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> (three on PB and two on PHT) had missing treatment failure time and did not contribute to analysis, but reasons for treatment failure were provided for the two participants on PHT. </p> <p>c.Other reasons from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>: participants developed other medical disorders including neurological and psychiatric disorders </p> </div> </div> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> did not record the randomised drug for six participants, and the reason for treatment failure was not available for one participant randomised to phenytoin and could not be determined from the case notes. Similarly, in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>, for three participants randomised to phenobarbitone, the reason for treatment failure was not available and could not be determined from the case notes. For another two participants randomised to phenytoin in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>, the reason for treatment failure was available, but the treatment failure time was not available for these participants. All participants completed the 12‐week trial in <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> and treatment failure data were not available for <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, so these two trials could not contribute to the analysis of 'time to treatment failure.' Therefore, 499 participants contributed to the analysis of 'time to treatment failure' and reasons for 501 participants are presented in <a href="#CD002217-tbl-0006">Table 4</a>. </p> <p>Out of the 501 participants for whom we had reasons for treatment failure or withdrawal (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>), 330 participants prematurely withdrew from treatment (66% of total participants): 156 out of 220 participants randomised to phenobarbitone (71%), and 174 out of 281 participants randomised to phenytoin (62%).<br/> <br/> We deemed 212 participants (64% of total treatment failures), to have withdrawn for reasons related to the trial drug, 111 (71% of total treatment failures), on phenobarbitone and 101 (58% of total treatment failures), on phenytoin, and we classed these reasons as 'events' in analysis. </p> <p>The most common treatment‐related reason for treatment failure was a combination of adverse events and lack of efficacy: 93 withdrawals (44% of total treatment failures); 53 (48% of total treatment failures) on phenobarbitone and 40 (40% of total treatment failures) on phenytoin. Non‐compliance with treatment or patient choice was the treatment‐related reason in 21% of total treatment failures, lack of efficacy in 21% of total treatment failures and adverse events in 14% of total treatment failures. </p> <p>We classed the other 94 reasons (32 on phenobarbitone and 62 on phenytoin), which were mostly losses to follow‐up (48% of other withdrawals) or participants going into remission (45% of other withdrawals), to be not related to the treatment and censored these participants in the analysis, in addition to the 171 participants (64 on phenobarbitone and 107 on phenytoin), who completed the trial without withdrawing or failing treatment. </p> <p>Considering time to treatment failure for any reason related to the treatment, the overall pooled HR (for 499 participants in three trials) was 1.61 (95% CI 1.22 to 2.12; P = 0.0007, low‐certainty evidence; <a href="./references#CD002217-fig-0017" title="">Analysis 1.1</a>), indicating that treatment failure occurs significantly earlier on phenobarbitone compared to phenytoin. However, a substantial amount of statistical heterogeneity was present between trials (I<sup>2</sup> = 71%). When analysis is repeated with random‐effects, the pooled HR was 2.10 (95% CI 1.09 to 4.05, P = 0.03), indicating that when variation between trials is accounted for, phenobarbitone was still significantly more likely to be withdrawn earlier than phenytoin but the confidence intervals of the pooled effect are wide, therefore we are unsure of the magnitude of the advantage to phenytoin. This heterogeneity is investigated further in subgroup analyses (see below). </p> <p>Considering time to treatment failure due to adverse events (all other reasons for treatment failure or treatment withdrawal censored in analysis), the overall pooled HR (for 499 participants in three trials), was 2.01 (95% CI 1.39 to 2.90; P = 0.0002; low‐certainty evidence; <a href="./references#CD002217-fig-0018" title="">Analysis 1.2</a>), indicating that treatment failure due to adverse events occurs significantly earlier on phenobarbitone compared to phenytoin. However, a substantial amount of statistical heterogeneity was present between trials (I<sup>2</sup> = 78%). When analysis is repeated with random‐effects, the pooled HR was 3.49 (95% CI 1.15 to 10.66, P = 0.03), indicating that when variation between trials is accounted for, phenobarbitone was still significantly more likely to be failed earlier than phenytoin but the confidence intervals of the pooled effect are wide, therefore we are unsure of the magnitude of the advantage to phenytoin. From visual inspection of the forest plot of <a href="./references#CD002217-fig-0018" title="">Analysis 1.2</a>, the HRs of one trial was around 1.5 (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) while the HRs of the other two trials were much larger (HR around 6 to 6.6 respectively) and confidence intervals of the HRs were very wide (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>). <a href="#CD002217-tbl-0006">Table 4</a> shows an imbalance between the drugs between the number of participants failing treatment due to adverse events in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> and <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; very few participants on phenytoin failed treatment due to adverse events compared to participants on phenobarbitone in these trials. This explains the extreme and imprecise HRs for these two trials and may explain the moderate amount of heterogeneity between trials. The heterogeneity is also investigated further in subgroup analyses (see below).<br/> <br/> Considering time to treatment failure due to lack of efficacy (all other reasons for treatment failure or treatment withdrawal censored in analysis), the overall pooled HR (for 499 participants in three trials) was 1.85 (95% CI 1.31 to 2.62; P = 0.0005, moderate‐certainty evidence; <a href="./references#CD002217-fig-0019" title="">Analysis 1.3</a>), indicating that treatment failure due to lack of efficacy occurs significantly earlier on phenobarbitone compared to phenytoin. No important heterogeneity was present between trials (I<sup>2</sup> = 15%). </p> <section id="CD002217-sec-0085"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>Considering time to treatment failure for any reason related to the treatment, for individuals with focal onset seizures (404 participants from three trials), the pooled HR was 1.46 (95% CI 1.09 to 1.96, P = 0.01, I<sup>2</sup> = 53%, low‐certainty evidence), indicating that treatment failure occurs significantly earlier on phenobarbitone compared to phenytoin. For individuals with generalised onset seizures (95 participants from two trials), the pooled HR was 4.04 (95% CI 1.61 to 10.14, P = 0.003, I² = 0%; low‐certainty evidence), indicating that treatment failure occurs significantly earlier on phenobarbitone compared to phenytoin. There is statistically significant evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.04, I² = 76.5%; <a href="./references#CD002217-fig-0020" title="">Analysis 1.4</a>), in other words, it appears that the treatment effect of phenytoin over phenobarbitone may be larger for individuals with generalised onset seizures compared to individuals with focal onset seizures. </p> <p>The overall pooled HR (adjusted by epilepsy type for 499 participants from three trials) was 1.61 (95% CI 1.22 to 2.12, P = 0.0008, low‐certainty evidence; <a href="./references#CD002217-fig-0020" title="">Analysis 1.4</a>), indicating that treatment failure occurs significantly earlier on phenobarbitone compared to phenytoin. </p> <p>A substantial amount of statistical heterogeneity was present between trials (I<sup>2</sup> = 53%) overall and for individuals with focal onset seizures. When analysis is repeated with random‐effects, the pooled HR for all individuals was 2.32 (95% CI 1.28 to 4.20, P = 0.005) and for individuals with focal onset seizures was 1.83 (95% CI 0.97 to 3.47, P = 0.06), indicating that when variation between trials is accounted for, the advantage to phenobarbitone is still statistically significant for all individuals, but no longer statistically significant for individuals with focal onset seizures. The confidence intervals of the pooled effect are wide for these random‐effect analyses, in addition to the confidence intervals of the pooled effect for individuals with generalised onset seizures (likely due to the small number of participants with generalised onset seizures failing treatment due to adverse events in these trials, see <a href="#CD002217-tbl-0006">Table 4</a>). Therefore we are unsure of the magnitude of the advantage to phenytoin overall and for both seizure types. In random‐effects analysis, there is no longer statistically significant evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.17, I² = 47.7). </p> <p>Considering time to treatment failure due to adverse events, for individuals with focal onset seizures (404 participants from three trials), the pooled HR was 1.86 (95% CI 1.27 to 2.73, P = 0.001, I<sup>2</sup> = 73%, low‐certainty evidence), indicating that treatment failure due to adverse events occurs significantly earlier on phenobarbitone compared to phenytoin. For individuals with generalised onset seizures (95 participants from two trials), the pooled HR was 4.60 (95% CI 1.17 to 17.98, P = 0.03, I² = 0%; low‐certainty evidence), indicating that treatment failure due to adverse events occurs significantly earlier on phenobarbitone compared to phenytoin. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.21, I² = 36.2%; <a href="./references#CD002217-fig-0021" title="">Analysis 1.5</a>). </p> <p>A substantial amount of statistical heterogeneity was present between trials (I<sup>2</sup> = 73%) for individuals with focal onset seizures. When analysis is repeated with random‐effects, the pooled HR was 3.52 (95% CI 1.04 to 11.95, P = 0.04), indicating that when variation between trials is accounted for, phenobarbitone was still significantly more likely to be failed earlier than phenytoin but the confidence intervals of the pooled effect are wide. The confidence intervals of the pooled effect are also wide for individuals with generalised onset seizures (likely due to the small number of participants with generalised onset seizures failing treatment due to adverse events in these trials, see <a href="#CD002217-tbl-0006">Table 4</a>). Therefore we are unsure of the magnitude of the advantage to phenytoin for both seizure types. </p> <p>The overall pooled HR (adjusted by epilepsy type for 499 participants from three trials) was 1.99 (95% CI 1.37 to 2.87, P = 0.0003, low‐certainty evidence; <a href="./references#CD002217-fig-0021" title="">Analysis 1.5</a>), indicating that treatment failure due to adverse events occurs significantly earlier on phenobarbitone compared to phenytoin. However, a substantial amount of statistical heterogeneity was present between trials (I<sup>2</sup> = 58%). When analysis is repeated with random‐effects, the pooled HR was 3.66 (95% CI 1.49 to 8.96, P = 0.005), indicating that when variation between trials is accounted for, phenobarbitone was still significantly more likely to be failed earlier than phenytoin but the confidence intervals of the pooled effect are wide, therefore we are unsure of the magnitude of the advantage to phenytoin. </p> <p>Considering time to treatment failure due to lack of efficacy, for individuals with focal onset seizures (404 participants from three trials), the pooled HR was 1.73 (95% CI 1.19 to 2.52, P = 0.004, I² = 0%; moderate‐quality evidence) and for individuals with generalised onset seizures (95 participants from two trials), the pooled HR was 3.40 (95% CI 1.21 to 9.54, P = 0.02, I² = 0%; low‐certainty evidence). Both results indicate that treatment failure due to lack of efficacy occurs significantly earlier on phenobarbitone compared to phenytoin, but for individuals with generalised onset seizures, the confidence intervals of the pooled effect are wide, therefore we are unsure of the magnitude of the advantage to phenytoin. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.23, I² = 31.1%; <a href="./references#CD002217-fig-0022" title="">Analysis 1.6</a>). </p> <p>The overall pooled HR (adjusted by epilepsy type for 499 participants from three trials) was 1.87 (95% CI 1.32 to 2.66, P = 0.0005, I<sup>2</sup> = 0%; moderate‐certainty evidence; <a href="./references#CD002217-fig-0022" title="">Analysis 1.6</a>), indicating that treatment failure due to lack of efficacy occurs significantly earlier on phenobarbitone compared to phenytoin. </p> </section> <section id="CD002217-sec-0086"> <h6 class="title">Additional subgroup analyses to investigate heterogeneity</h6> <p>A large amount of heterogeneity (I<sup>2</sup> &gt; 70%) was present in the analyses of 'Time to treatment failure (any reason related to treatment)' and 'Time to treatment failure due to adverse events' for all participants (see <a href="./references#CD002217-fig-0017" title="">Analysis 1.1</a>, <a href="./references#CD002217-fig-0018" title="">Analysis 1.2</a>). This heterogeneity does not seem to be completely explained by differences in seizure type (focal versus generalised onset) as a large amount of heterogeneity (I<sup>2</sup> &gt; 50%) is still present for these outcomes for individuals with focal onset seizures (see <a href="./references#CD002217-fig-0020" title="">Analysis 1.4</a>, <a href="./references#CD002217-fig-0021" title="">Analysis 1.5</a>). We considered two further possible sources of heterogeneity, age of the participants recruited and presence of blinding in the study. </p> <p> <ul id="CD002217-list-0013"> <li> <p>We performed a subgroup analysis combining two studies of adults (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) compared with a study of children only (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>). </p> <ul id="CD002217-list-0014"> <li> <p>Considering time to treatment failure for any reason related to the treatment, for 436 adults, the pooled HR is 1.46 (95% CI 1.09 to 1.95, P = 0.01, I<sup>2</sup>=57%) and for the 63 children, the HR is 3.93 (95% CI 1.65 to 9.34, P = 0.002). There is statistically significant evidence of an interaction between age of the participants (adults versus children) and treatment effect (test of subgroup differences: P = 0.03, I² = 78.0%, <a href="./references#CD002217-fig-0023" title="">Analysis 1.7</a>). </p> </li> <li> <p>Considering time to treatment failure due to adverse events, for 436 adults, the pooled HR is 1.75 (95% CI 1.18 to 2.58, P = 0.005, I<sup>2</sup> = 80%) and for the 63 children, the HR is 5.99 (95% CI 1.99 to 17.96, P = 0.001). There is statistically significant evidence of an interaction between age of the participants (adults versus children) and treatment effect (test of subgroup differences: P = 0.04, I² = 76.6%, <a href="./references#CD002217-fig-0024" title="">Analysis 1.8</a>). </p> </li> <li> <p>In other words, for both adults and children, a significant advantage is observed for phenytoin (i.e. treatment failure for any reason or due to adverse events occurs later on phenytoin than phenobarbitone) and this advantage to phenytoin seems to be significantly larger for children compared to adults. </p> </li> <li> <p>However, the heterogeneity present within the analyses of these outcomes still does not seem to be completely explained by differences in the age of participants as a large amount of heterogeneity (I<sup>2</sup> &gt; 50%) is still present for these outcomes for adults. </p> </li> </ul> </li> <li> <p>We performed a subgroup analysis combining two open‐label studies (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>) compared with a double‐blinded study (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>). </p> <ul id="CD002217-list-0015"> <li> <p>Considering time to treatment failure for any reason related to the treatment, in the open‐label studies (179 participants), the pooled HR is 2.92 (95% CI 1.69 to 5.03, P = 0.0001, I<sup>2</sup>= 0%) and in the double‐blind study (320 participants), the HR is 1.31 (95% CI 0.95 to 1.81, P = 0.09). There is statistically significant evidence of an interaction between presence of blinding (open‐label design versus double‐blind design) and treatment effect (test of subgroup differences: P = 0.01, I² = 83.6%, <a href="./references#CD002217-fig-0025" title="">Analysis 1.9</a>). </p> </li> <li> <p>Considering time to treatment failure due to adverse events, in the open‐label studies (179 participants), the pooled HR is 6.25 (95% CI 2.75 to 14.22, P &lt; 0.0001, I<sup>2</sup> = 0%) and in the double‐blind study (320 participants), the HR is 1.51 (95% CI 1.00 to 2.28, P = 0.05). There is statistically significant evidence of an interaction between presence of blinding (open‐label design versus double‐blind design) and treatment effect (test of subgroup differences: P = 0.002, I² = 89.1%, <a href="./references#CD002217-fig-0026" title="">Analysis 1.10</a>). </p> </li> <li> <p>In other words, a significant advantage is observed for phenytoin in the open‐label trials (i.e. treatment failure for any reason or due to adverse events occurs later on phenytoin than phenobarbitone, but we are unsure of the magnitude of this advantage as the confidence intervals around the effect size are wide). In the double‐blind trial, there was no statistically significant difference between the treatments in terms of treatment failure for any reason related to the treatment but a significant advantage for phenytoin in terms of treatment failures due to adverse events (i.e. treatment failure due to adverse events occurs later on phenytoin than phenobarbitone). </p> </li> <li> <p>The heterogeneity present within the analyses of these outcomes seems to be explained by the differences in treatment effect in the open‐label and the double‐blinded studies. Important differences in treatment effect in open‐label and double‐blinded epilepsy monotherapy studies have also been observed in other reviews in our series of pair‐wise reviews for monotherapy in epilepsy (<a href="./references#CD002217-bbs2-0046" title="NevittSJ , Tudur SmithC , WestonJ , MarsonAG . Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 6. [DOI: 10.1002/14651858.CD001031.pub4] ">Nevitt 2018a</a>; <a href="./references#CD002217-bbs2-0049" title="NevittSJ , MarsonAG , Tudur‐SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2018, Issue 10. [DOI: 10.1002/14651858.CD001904.pub4] ">Nevitt 2018d</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD002217-sec-0087"> <h6 class="title">Sensitivity analysis</h6> <p>We conducted sensitivity analyses to investigate misclassification of seizure type, following reclassification of the 33 participants aged 30 or older in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> with new onset generalised seizures reclassified to focal onset seizures or an uncertain seizure type (see <a href="#CD002217-sec-0061">Sensitivity analysis</a> for further details). For the outcomes, 'Time to treatment failure (any reason related to treatment)' and 'Time to treatment failure due to adverse events,' following sensitivity analysis, results were numerically similar and conclusions were unchanged (i.e. a statistically significant advantage for phenytoin over phenobarbitone was observed for all participants, for individuals with focal onset seizures and for individuals with generalised onset seizures but we are uncertain of the magnitude of the advantage for phenytoin, particularly for individuals with generalised onset seizures). Heterogeneity remained within analysis for all participants (I<sup>2</sup> between 44% and 59%) and for individuals with focal onset seizures (I<sup>2</sup> between 53% and 79%) and there was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect following sensitivity analysis (see <a href="#CD002217-tbl-0007">Table 5</a> for all sensitivity analysis results). </p> <div class="table" id="CD002217-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Original analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. "><b>de Silva 1996</b> </a> </p> <p><b>(sensitivity analysis)<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Generalised onset and age at onset &gt; 30 years classified as focal onset</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Generalised onset and age at onset &gt; 30 years classified as uncertain seizure type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure</p> <p>(for any reason related to treatment)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.46 (1.09 to 1.96), I² = 53% </p> <p><b>G:</b> 4.04 (1.61 to 10.14), I² = 0% </p> <p><b>O:</b> 1.61 (1.22 to 2.12), I² = 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 4.25, df = 1, P = 0.04, I² = 76.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.36 (1.01 to 1.84), I² = 0% </p> <p><b>G:</b> 4.22 (1.39 to 12.86), I² = 0% </p> <p><b>O:</b> 1.47 (1.10 to 1.97), I² = 4% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.68, df = 1, P = 0.06, I² = 72.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.54 (1.15 to 2.06), I² = 66% </p> <p><b>G:</b> 3.18 (1.15 to 8.76), I² = 0% </p> <p><b>O:</b> 1.63 (1.23 to 2.15), I² = 48% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.81, df = 1, P = 0.18, I² = 44.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.46 (1.09 to 1.96), I² = 53% </p> <p><b>G:</b> 3.18 (1.15 to 8.76), I² = 0% </p> <p><b>U</b>: 9.08 (1.01 to 81.51), I² = NA </p> <p><b>O</b>: 1.60 (1.21 to 2.11), I² = 44% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 4.52, df = 2, P = 0.10, I² = 55.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.86 (1.27 to 2.73), I² = 73% </p> <p><b>G:</b> 4.60 (1.17 to 17.98), I² = 0% </p> <p><b>O:</b> 1.99 (1.37 to 2.87), I² = 58% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.57, df = 1, P = 0.21, I² = 36.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.65 (1.11 to 2.46), I² = 27% </p> <p><b>G:</b> 5.04 (1.04 to 24.53), I² = 0% </p> <p><b>O:</b> 1.76 (1.20 to 2.59), I² = 21% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.80, df = 1, P = 0.18, I² = 44.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.92 (1.31 to 2.81), I² = 79% </p> <p><b>G:</b> 3.01 (0.75 to 12.07), I² = 0% </p> <p><b>O:</b> 1.98 (1.37 to 2.86), I² = 59% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.37, df = 1, P = 0.54, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not available<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to lack of efficacy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.73 (1.19 to 2.52), I² = 0% </p> <p><b>G:</b> 3.40 (1.21 to 9.54), I² = 0% </p> <p><b>O:</b> 1.87 (1.32 to 2.66), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.45, df = 1, P = 0.23, I² = 31.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.66 (1.13 to 2.44), I² = 0% </p> <p><b>G:</b> 3.22 (0.85 to 12.21), I² = 0% </p> <p><b>O:</b> 1.75 (1.21 to 2.53), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.88, df = 1, P = 0.35, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.76 (1.22 to 2.55), I² = 0% </p> <p><b>G:</b> 3.44 (1.11 to 10.72), I² = 0% </p> <p><b>O:</b> 1.88 (1.32 to 2.67), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.21, df = 1, P = 0.27, I² = 17.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.73 (1.19 to 2.52), I² = 0% </p> <p><b>G:</b> 3.44 (1.11 to 10.72), I² = 0% </p> <p><b>U</b>: 2.46 (0.15 to 39.49), I² = NA </p> <p><b>O</b>: 1.86 (1.31 to 2.64), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.31, df = 2, P = 0.52, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first seizure<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.81 (0.63 to 1.04), I² = 0% </p> <p><b>G</b>: 1.06 (0.70 to 1.62), I² = 27% </p> <p><b>O:</b> 0.87 (0.70 to 1.08), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.17, df = 1, P = 0.28, I² = 14.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.83 (0.64 to 1.08), I² = 0% </p> <p><b>G:</b> 1.00 (0.65 to 1.55), I² = 5% </p> <p><b>O:</b> 0.87 (0.70 to 1.09), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.50, df = 1 (P = 0.48), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.83 (0.65 to 1.06), I² = 0% </p> <p><b>G:</b> 1.08 (0.65 to 1.79), I² = 0% </p> <p><b>O:</b> 0.87 (0.70 to 1.09), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.81, df = 1, P = 0.37, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.81 (0.63 to 1.04), I² = 0% </p> <p><b>G:</b> 1.08 (0.65 to 1.79), I² = 0% </p> <p><b>U</b>: 1.04 (0.43 to 2.50), I² = 0% </p> <p><b>O</b>: 0.87 (0.69 to 1.08), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.15, df = 2, P = 0.56, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 12‐month remission<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.96 (0.70 to 1.33), I² = 9% </p> <p><b>G:</b> 0.77 (0.46 to 1.28), I² = 0% </p> <p><b>O:</b> 0.90 (0.69 to 1.19), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.53, df = 1, P = 0.47, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.89 (0.63 to 1.24), I² = 3% </p> <p><b>G:</b> 0.78 (0.46 to 1.31), I² = 0% </p> <p><b>O:</b> 0.85 (0.64 to 1.13), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.18, df = 1 (P = 0.67), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.97 (0.72 to 1.31), I² = 8% </p> <p><b>G:</b> 0.54 (0.28 to 1.07), I² = 0% </p> <p><b>O:</b> 0.88 (0.67 to 1.16), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.37, df = 1, P = 0.12, I² = 57.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.96 (0.70 to 1.33), I² = 9% </p> <p><b>G:</b> 0.54 (0.28 to 1.07), I² = 0% </p> <p><b>U</b>: 1.00 (0.43 to 2.32), I² = NA </p> <p><b>O</b>: 0.88 (0.67 to 1.16), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.36, df = 2, P = 0.31, I² = 15.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 6‐month remission<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b>: 0.94 (0.71 to 1.25), I² = 0% </p> <p><b>G:</b> 0.82 (0.52 to 1.29), I² = 30% </p> <p><b>O:</b> 0.91 (0.71 to 1.15), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.27, df = 1, P = 0.60, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.89 (0.67 to 1.19), I² = 0% </p> <p><b>G:</b> 0.84 (0.53 to 1.34), I² = 22% </p> <p><b>O:</b> 0.88 (0.69 to 1.12), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.05, df = 1 (P = 0.82), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b> 0.93 (0.72 to 1.21)<b>:</b>, I² = 0% </p> <p><b>G:</b> 0.65 (0.35 to 1.20), I² = 45% </p> <p><b>O:</b> 0.88 (0.69 to 1.12), I² = 16% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.10, df = 1, P = 0.29, I² = 8.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b>: 0.94 (0.71 to 1.25), I² = 0% </p> <p><b>G:</b> 0.65 (0.35 to 1.20), I² = 45% </p> <p><b>U</b>: 0.87 (0.40 to 1.88), I² = NA </p> <p><b>O</b>: 0.88 (0.69 to 1.13), I² = 2% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.16, df = 2, P = 0.56, I² = 0%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Chi²: Chi² statistic; df: degrees of freedom of Chi² distribution; F: focal epilepsy; G: generalised epilepsy; NA: not applicable; O: overall (all participants); P: P value (&lt; 0.05 are classified as statistically significant); U: uncertain epilepsy. </p> <p>a. For time to treatment failure and time to first seizure, HR &lt; 1 indicates a clinical advantage for carbamazepine and for time to 12‐month and six‐month remission, HR &lt; 1 indicates a clinical advantage for phenobarbitone. All results presented are calculated from fixed‐effect meta‐analysis. </p> <p>b. 33 participants reclassified to focal epilepsy or uncertain epilepsy type from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>. Heterogeneity (I<sup>2</sup>) is not applicable for the uncertain epilepsy type group as only one study (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>) contributes to this estimate. </p> <p>c. 46 participants reclassified to focal epilepsy or uncertain epilepsy type from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>. </p> <p>d. Sensitivity analysis including only the participants in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, who were randomised before the phenobarbitone arm was withdrawn. </p> <p>e. This sensitivity analysis could not be conducted as no individuals with uncertain seizure type withdrew from phenytoin in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </div> </div> <p>We also conducted sensitivity analysis including only the 19 participants randomised in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> before the phenobarbitone arm was discontinued due to adverse events (see <a href="#CD002217-sec-0061">Sensitivity analysis</a> for further details). For the outcomes, 'Time to treatment failure (any reason related to treatment)' and 'Time to treatment failure due to adverse events,' following sensitivity analysis, results were quite numerically similar and conclusions were unchanged (as above). However, following this sensitivity analysis, heterogeneity was greatly reduced in analyses for all participants (from I<sup>2</sup> &gt; 50% in both analyses to I<sup>2</sup> = 21% and 4% respectively) and for individuals with focal onset seizures (I<sup>2</sup> = 53% reduced to 0% and I<sup>2</sup> = 73% reduced to 27% respectively). There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect following sensitivity analysis (see <a href="#CD002217-tbl-0007">Table 5</a> for all sensitivity analysis results). </p> <p>Considering time to treatment failure due to lack of efficacy, for all of the sensitivity analyses, results were numerically similar and conclusions were unchanged (see <a href="#CD002217-tbl-0007">Table 5</a>). </p> </section> </section> </section> <section id="CD002217-sec-0088"> <h4 class="title">Secondary outcomes</h4> <section id="CD002217-sec-0089"> <h5 class="title">Time to first seizure</h5> <p>For this outcome, an HR less than 1 indicates a clinical advantage for phenobarbitone.</p> <p>Time to first seizure after randomisation was available for 624 individuals in all five trials supplying IPD (98.3% of 635 participants from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and 78.2% of the total 798 participants from the seven included trials). Dates of seizure recurrence were not available for seven participants in <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and four participants in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, therefore, we did not include these 14 participants in the analysis. Three hundred and sixty‐three out of 624 participants (58%), experienced seizure recurrence, 142 out of 281 (51%), on phenobarbitone and 221 out of 343 (64%) on phenytoin. The overall pooled HR (for 624 participants) was 0.85 (95% CI 0.69 to 1.06, P = 0.14, moderate‐certainty evidence, <a href="./references#CD002217-fig-0027" title="">Analysis 1.11</a>), indicating a potential advantage to phenobarbitone which was not statistically significant; in other words, seizure recurrence may occur earlier on phenytoin than phenobarbitone, but we cannot rule out an advantage to phenytoin or no difference between the drugs. There was no evidence of any statistical heterogeneity between trials (I² = 0%). </p> <section id="CD002217-sec-0090"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>For participants with focal seizures (463 from five trials), the pooled HR was 0.81 (95% CI 0.63 to 1.04, P = 0.10, I<sup>2</sup>=0%, moderate‐certainty evidence) indicating a potential advantage to phenobarbitone which was not statistically significant; in other words, seizure recurrence may occur earlier on phenytoin than phenobarbitone, but we cannot rule out an advantage to phenytoin or no difference between the drugs. For participants with generalised seizures (161 from four trials), the pooled HR was 1.06 (95% CI 0.70 to 1.62 , P = 0.79, I<sup>2</sup>=27%, moderate certainty evidence) indicating no clear advantage for either drug. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.28, I² = 14.4%; <a href="./references#CD002217-fig-0028" title="">Analysis 1.12</a>). </p> <p>Overall, the pooled HR (adjusted for seizure type) is 0.87 (95% CI 0.70 to 1.08, P = 0.21, moderate‐certainty evidence) indicating a potential advantage to phenobarbitone which was not statistically significant. </p> </section> <section id="CD002217-sec-0091"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only the 19 participants randomised in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> before the phenobarbitone arm was discontinued due to adverse events and to investigate misclassification of seizure type, following reclassification of the 46 participants aged 30 or older in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> with new onset generalised seizures reclassified to focal onset seizures or an uncertain seizure type (see <a href="#CD002217-sec-0061">Sensitivity analysis</a> for further details), results were very similar and conclusions were unchanged (see <a href="#CD002217-tbl-0007">Table 5</a>). </p> </section> </section> <section id="CD002217-sec-0092"> <h5 class="title">Time to 12‐month remission</h5> <p>For this outcome, an HR less than 1 indicates a clinical advantage for phenytoin.</p> <p>Time to 12‐month remission was available for 588 individuals from four out of the five trials supplying IPD (98.2% of 599 participants from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and 73.7% of the total 798 participants from the seven included trials). Dates of seizure recurrence were not available for seven participants in <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and four participants in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, therefore, we did not include these 14 participants in the analysis and <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> was a trial of 12‐week duration, therefore 'time to 12‐month remission' could not be calculated for this trial. Two hundred and forty‐nine out of 588 participants (42%) achieved 12‐month remission, 91 out of 263 (34%), on phenobarbitone and 158 out of 325 (49%) on phenytoin. The overall pooled HR (for 588 participants) was 0.90 (95% CI 0.69 to 1.18, P = 0.44, moderate‐certainty evidence, <a href="./references#CD002217-fig-0029" title="">Analysis 1.13</a>), indicating no clear advantage between the drugs. There was no evidence of any important statistical heterogeneity between trials (I² = 0%). </p> <section id="CD002217-sec-0093"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>The length of follow‐up in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> was 12 months and only 19 of the original 94 participants in the trial completed 12 months of follow‐up and of these 19 participants, only eight (one generalised seizures, seven focal seizures) achieved 12‐month remission. Therefore, the HR estimate for individuals with focal seizures in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> is based on small numbers and the HR for individuals with generalised seizures is not estimable as only one participant had a event (see <a href="./references#CD002217-fig-0030" title="">Analysis 1.14</a>). </p> <p>For participants with focal seizures (458), the pooled HR was 0.96 (95% CI 0.70 to 1.33, P = 0.82, I<sup>2</sup>= 9%, moderate‐certainty evidence) indicating no clear advantage for either drug. For participants with generalised seizures (130), the pooled HR was 0.77 (95% CI 0.46 to 1.28 , P = 0.31, I<sup>2</sup> = 0%, moderate‐certainty evidence) indicating a potential advantage for phenytoin, which is not statistically significant; in other words, 12‐month remission may occur earlier on phenytoin compared to phenobarbitone but we cannot rule out an advantage to phenobarbitone or no difference between drugs. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.47, I² = 0%; <a href="./references#CD002217-fig-0030" title="">Analysis 1.14</a>). </p> <p>Overall, the pooled HR (adjusted for seizure type) is 0.90 (95% CI 0.69 to 1.19, P = 0.46, moderate‐certainty evidence) indicating no clear advantage for either drug. </p> </section> <section id="CD002217-sec-0094"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only the 19 participants randomised in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> before the phenobarbitone arm was discontinued due to adverse events and to investigate misclassification of seizure type, following reclassification of the 33 participants aged 30 or older in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> with new onset generalised seizures reclassified to focal onset seizures or an uncertain seizure type (see <a href="#CD002217-sec-0061">Sensitivity analysis</a> for further details), results were very similar and conclusions were unchanged (see <a href="#CD002217-tbl-0007">Table 5</a>). </p> </section> </section> <section id="CD002217-sec-0095"> <h5 class="title">Time to six‐month remission</h5> <p>For this outcome, an HR less than 1 indicates a clinical advantage for phenytoin.</p> <p>Time to six‐month remission was available for 588 individuals from four out of the five trials supplying IPD (98.2% of 599 participants from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and 73.7% of the total 798 participants from the seven included trials). Dates of seizure recurrence were not available for seven participants in <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and four participants in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>, therefore, we did not include these 14 participants in the analysis and <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> was a trial of 12‐week duration, therefore 'time to six‐month remission' could not be calculated for this trial. Three hundred and eleven out of 588 participants (53%) achieved six‐month remission, 122 out of 263 (46%), on phenobarbitone and 189 out of 325 (58%) on phenytoin. The overall pooled HR (for 588 participants) was 0.93 (95% CI 0.73 to 1.18, P = 0.53, moderate‐certainty evidence, <a href="./references#CD002217-fig-0031" title="">Analysis 1.15</a>), indicating no clear advantage between the drugs. There was no evidence of any important statistical heterogeneity between trials (I² = 21%). </p> <section id="CD002217-sec-0096"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>For participants with focal seizures (458), the pooled HR was 0.94 (95% CI 0.71 to 1.25, P = 0.69, I<sup>2</sup> = 0%, moderate‐certainty evidence) indicating no clear advantage for either drug. For participants with generalised seizures (130), the pooled HR was 0.82 (95% CI 0.52 to 1.29 , P = 0.39, I<sup>2</sup>=30%, moderate‐certainty evidence) indicating a potential advantage for phenytoin, which is not statistically significant; in other words, six‐month remission may occur earlier on phenytoin compared to phenobarbitone but we cannot rule out an advantage to phenobarbitone or no difference between drugs. There was no evidence of an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect (test of subgroup differences: P = 0.60, I² = 0%; <a href="./references#CD002217-fig-0032" title="">Analysis 1.16</a>). </p> <p>Overall, the pooled HR (adjusted for seizure type) is 0.91 (95% CI 0.71 to 1.15, P = 0.43, moderate‐certainty evidence) indicating no clear advantage for either drug. </p> </section> <section id="CD002217-sec-0097"> <h6 class="title">Sensitivity analysis</h6> <p>In the sensitivity analyses including only the 19 participants randomised in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> before the phenobarbitone arm was discontinued due to adverse events and to investigate misclassification of seizure type, following reclassification of the 33 participants aged 30 or older in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> with new onset generalised seizures reclassified to focal onset seizures or an uncertain seizure type (see <a href="#CD002217-sec-0061">Sensitivity analysis</a> for further details), results were very similar and conclusions were unchanged (see <a href="#CD002217-tbl-0007">Table 5</a>). </p> <p>In <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>, there is evidence that the proportional hazards assumption of the Cox regression model is violated (see <a href="#CD002217-sec-0059">Data synthesis</a>); the P value of time varying covariate is 0.013 and from visual inspection of the survival plot (<a href="#CD002217-fig-0016">Figure 16</a>), the curves cross and hazards become non‐proportional around 300 days. In other words, it appears that the treatment effect is not constant throughout follow‐up, and this change seems to happen at around 300 days. As <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> provides over half of the data contributing to this outcome, sensitivity analysis was performed for all participants by analysing separately those who achieved six‐month remission of seizures before and after 300 days using a piecewise Cox regression model is fitted to investigate any change in treatment effect over time, assuming proportional hazards within each interval. </p> <div class="figure" id="CD002217-fig-0016"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 16</div> </div> <hr class="top"/><img alt="Time to 6 month remission ‐ Mattson 1985 (Proportional Hazards Check)" data-id="CD002217-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG16.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 6 month remission ‐ <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> (Proportional Hazards Check) </p> </div> </div> </div> <p>The follow‐up period of the four trials is split into two intervals (0 to 300 days and after 300 days) and separate HRs can be estimated for each interval in each trial. Seventy‐four (13%) out of 588 participants achieved six‐month remission of seizures after 300 days (20 from <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, 30 from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>, 24 from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and none from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). </p> <p>For interval 0 to 300 days (237 events from 588 participants at risk), the pooled HR was 1.03 (95% CI 0.79 to 1.34, P = 0.85, I<sup>2</sup>=0%, <a href="./references#CD002217-fig-0033" title="">Analysis 1.17</a>), suggesting no clear advantage to either drug. </p> <p>For interval after 300 days (74 events in 113 participants at risk), the pooled HR was 0.78 (95% CI 0.60 to 1.00, P=0.05, I<sup>2</sup> = 19%, <a href="./references#CD002217-fig-0033" title="">Analysis 1.17</a>), indicating a statistically significant advantage to phenytoin. </p> <p>In other words, in terms of 'early' remissions up to 300 days there appears to be no difference between drugs but 'later' remission may occur significantly earlier on phenytoin than phenobarbitone. However, care is needed with interpretation as these results may be influenced by the smaller number of participants at risk at later time points and by the treatment failure and withdrawal rates from the drugs (see results of Primary Outcome 'Time to treatment failure' (retention time)). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD002217-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD002217-sec-0098"></div> <section id="CD002217-sec-0099"> <h3 class="title" id="CD002217-sec-0099">Summary of main results</h3> <p>Results for the primary outcome 'time to treatment failure for any reason related to treatment', in addition to the outcomes 'time to treatment failure due to adverse events' and 'time to treatment failure due to lack of efficacy' suggest a statistically significant advantage to phenytoin over phenobarbitone for 499 participants from three trials; in other words, treatment failure may occur significantly earlier on phenobarbitone than phenytoin. This advantage is observed for all participants, for the subgroup of individuals with focal onset seizures and for the subgroup of individuals with generalised onset seizures. There may be an interaction between epilepsy type (focal onset versus generalised onset) and treatment effect, i.e. the treatment effect of phenytoin over phenobarbitone may be larger for individuals with generalised onset seizures compared to individuals with generalised onset seizures. However, the results and the subgroup analyses for 'time to treatment failure for any reason related to treatment' and 'time to treatment failure due to adverse events' are confounded by large amounts of heterogeneity present overall and for individuals with focal onset seizures and we are uncertain of the magnitude of the advantage for phenytoin due to wide confidence intervals around the pooled treatment effect for all outcomes, particularly for individuals with generalised onset seizures. </p> <p>Additional sensitivity and subgroup analyses and sensitivity analyses show that misclassification of seizure type does not appear to have impacted on the results and that there appears to be an interaction between the age of the participants and treatment effect (the advantage to phenytoin seems to be significantly larger for children compared to adults), but the age of the participants in the included trials does not seem to explain the observed heterogeneity. </p> <p>On the other hand, there also appears to be an interaction between the presence of blinding in the studies and treatment effect and the heterogeneity present within the analyses does seem to be explained by the differences in treatment effect in the open‐label and the double‐blinded studies. An additional source of heterogeneity also seems to be a paediatric trial in which the phenobarbitone arm was withdrawn from the trial due to concerns over adverse events. </p> <p>All of these factors may have confounded the results of our primary analyses in this review and therefore results should be interpreted with caution. </p> <p>Results for secondary outcomes indicate that for all participants, considering time to first seizure post‐randomisation, seizure recurrence may occur earlier on phenytoin than phenobarbitone, but we cannot rule out an advantage to phenytoin or no difference between the drugs. There was no clear differences between the drugs in terms of time to 12‐month and six‐month remission. Results were similar when considering subgroups of individuals with focal onset seizures and subgroups of individuals with generalised onset seizures, and following sensitivity analyses of secondary outcomes, results were numerically similar and conclusions unchanged. </p> <p>However, confidence intervals around summary estimates are relatively wide for secondary outcomes and do not suggest equivalence. Furthermore, secondary outcomes may have been confounded by the significantly higher treatment failure rate and significantly earlier time to treatment failure of phenobarbitone compared to phenytoin. Therefore, as for the primary analysis in this review, results should be interpreted with caution. </p> </section> <section id="CD002217-sec-0100"> <h3 class="title" id="CD002217-sec-0100">Overall completeness and applicability of evidence</h3> <p>We have gratefully received individual participant data (IPD) for 635 individuals (80% of individuals from all eligible trials), from the authors of five trials (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>), which included a comparison of phenobarbitone with phenytoin for the treatment of epilepsy. We could not include 163 individuals (20%) from the other two relevant trials (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>), in any analysis, as IPD were not available and the published reports did not report outcomes of interest. </p> <p>While we received IPD for 635 participants, we were not able to include all data in all of our analyses. Because of the short, three‐month duration of the trial, we were unable to include 36 participants from <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> in our remission analyses, and in this short follow‐up time, no participants withdrew from treatment; therefore, this trial could not contribute to our primary outcome of 'time to treatment failure' either. We were also unable to include 110 participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> in analyses of treatment failure as treatment failure information was not available. Therefore, our primary outcome was, in fact, based on 499 participants (63% of individuals from all eligible trials). </p> <p>Having to exclude data for between 20% and 40% of the eligible participants due to lack of IPD and insufficient reporting in trial publications was likely to have had an impact on the applicability of the evidence; therefore, we encourage caution in the interpretation of all results in this review. However, it was difficult to quantify exactly how large this impact was on the results of this review (see <a href="#CD002217-sec-0102">Potential biases in the review process</a>). </p> <p>Three trials contributing around 73% of the participant data to this review recruited adults only (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>); the other two trials contributing around 27% of data were paediatric trials (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). Also, the largest single trial contributing over a third of the participant data to this review, <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>, recruited individuals with focal onset seizures only and recruited participants who were described as "untreated" or "undertreated." It was unclear how many participants were "undertreated" and how "undertreated" was defined in the study; i.e. it is unclear whether it be assumed that participants with no prior treatment and a small amount of prior treatment are clinically similar. </p> <p>Only 26% of participants included in this review were experiencing generalised onset seizures, which is reflected in the confidence intervals around summary effect sizes for individuals with generalised onset seizures, which are much wider than within the analyses of individuals wit focal onset seizures. Furthermore, there is evidence within this review to suggest that up to 28% of individuals with newly onset generalised seizures may have had their seizure type misclassified. For these reasons, the results of this review may not be fully generalisable to children or to individuals with generalised onset seizures, and more evidence recruiting these types of participants is required. </p> <p><a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> classified generalised and focal onset seizures according to the International League Against Epilepsy (ILAE), classification of 1981 (<a href="./references#CD002217-bbs2-0021" title="Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures.. Epilepsia1981;22(4):489‐501. ">Commission 1981</a>), rather than the revised ILAE classification in 1989 (<a href="./references#CD002217-bbs2-0022" title="Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia1989;30(4):389‐99. ">Commission 1989</a>), which may have led to misclassification. Furthermore, <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> was conducted in Nigeria, a lower middle‐income country without access to the same facilities as trials conducted in the USA and Europe; therefore, seizure types were classified clinically, and electroencephalographics (EEGs)/magnetic resonance images (MRIs), were not required for diagnosis of epilepsy. Clinical classification may also have contributed to potential misclassification in this trial. </p> <p>In three of the five trials (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>), participants and personnel were unblinded to treatment allocation (outcome assessors were blinded in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). It is however, debatable whether double‐blind design is the most appropriate for trials of monotherapy in epilepsy of long duration, and whether such a design does have an impact upon the dropout rate, and therefore, the results of the trial. The authors of the three unblinded trials state that blinding would not have been "practical" or "ethical" and would have resulted in a large withdrawal rate as blinding does not conform to standard clinical practice of increasing drug doses to therapeutic ranges (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>). This effect is demonstrated by the unblinded study (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>) with a 29% treatment withdrawal rate (34 out of 116 participants withdrew from treatment, 40% from phenobarbitone and 20% from phenytoin) and the blinded study (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>) with a 48% treatment withdrawal rate (152 out of 320 participants withdrew from treatment, 51% from phenobarbitone and 44% from phenytoin). The unblinded study (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>) had a treatment withdrawal rate of 40% (25 out of 63 participants), however, this rate is influenced by the high withdrawal rate of phenobarbitone (eight out of 10 (80%) participants withdrew from phenobarbitone while 17 out of 53 (32%) withdrew from phenytoin). </p> <p>As further discussed in <a href="#CD002217-sec-0099">Summary of main results</a>, the differences between the open‐label and double‐blinded studies, suggests a potential explanation for the heterogeneity observed; clinicians, particularly clinicians in the UK, may have a prior opinion of particular anti‐epileptic drugs and may expect adverse effects from phenobarbitone and would therefore be more likely to withdraw participants from this drug in an unblinded trial. Further, it is interesting to note that the UK trial recruiting children (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>) suspended randomisation to phenobarbitone due to serious adverse effects after 10 children had been randomised to that drug, whereas this problem was not reported in a trial recruiting children conducted in India (<a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>), in which phenobarbitone is concluded to be an "effective and acceptable antiepileptic drug for rural Indian children." These two studies may have been conducted from different perspectives due to the country of recruitment; <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> in the UK where concerns had been raised over the suitability of drugs such as phenobarbitone due to documented cases of adverse effects and <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> in rural India where income is limited, newer generation antiepileptic drugs (AEDs) are not readily available or affordable and therefore, drugs such as phenobarbitone are more likely to be used. We note the influence of country of recruitment over the methodological design and perhaps the results of the trial. Within the USA and Europe, where many treatment options are available, phenobarbitone is no longer considered to be a first‐line agent, in favour of more tolerable first‐line agents, such as carbamazepine and lamotrigine (<a href="./references#CD002217-bbs2-0052" title="National Institute for Health and Care Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence. Clinical Guidance 137; available from: https://www.nice.org.uk/guidance/cg137/resources/epilepsies‐diagnosis‐and‐management‐35109515407813 (accessed 18 December 2018).2012. ">NICE 2012</a>), whereas in low‐ and middle‐income countries or rural regions, where income is limited and newer generation antiepileptic drugs are not readily available or affordable, older and cheaper drugs, such as phenobarbitone, are more likely to be used as comparators. </p> <p>As described in <a href="#CD002217-sec-0099">Summary of main results</a>, results of this review are likely to be confounded by heterogeneity in design and methodological inadequacies of the included trials. Therefore, this apparent association may not be a true association and all results of this review should be interpreted with caution. We would not advocate basing a choice between these two drugs on the results of this review alone. </p> </section> <section id="CD002217-sec-0101"> <h3 class="title" id="CD002217-sec-0101">Quality of the evidence</h3> <p>The five trials for which IPD were made available were generally of relatively good methodological quality; however, three out of the five trials for which we received IPD were at high risk of bias for at least one aspect (see <a href="#CD002217-fig-0003">Figure 3</a>), which may have introduced bias into analyses. Three of the trials contributing 47% of the participant data to this review described adequate methods of randomisation and allocation concealment (<a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>; <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>; <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>); however, the other two largest single trials contributing 53% of participant data to this review did not describe the method of randomisation or allocation concealment used, or both, and this information was not available from trial authors (<a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>; <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>). We are uncertain whether this lack of information has affected the results of this review. As further discussed in <a href="#CD002217-sec-0099">Summary of main results</a> and <a href="#CD002217-sec-0100">Overall completeness and applicability of evidence</a>, the differences in design of the trials with respect to blinding was likely to have impacted on the results of the primary outcome 'time to treatment failure', and in turn, the treatment failure rates may have impacted on the secondary efficacy outcomes of time to first seizure and time to 12‐month and six‐month remission. </p> <p>Trials for which no IPD were available were generally of poorer quality than those for which we received IPD (<a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a>; <a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a>), particularly <a href="https://archie.cochrane.org/sections/documents/view?version=z1810161445427693100361160184097%26format=REVMAN#STD-Czapinski-1997" target="_blank">Czapinski 1997</a>, which was available only in abstract form and provided only very limited information on trial methodology </p> <p>Overall, due to the documented methodological issues that may have introduced heterogeneity, biases and imprecision into our meta‐analyses, we rated the evidence provided in this review as low quality (certainty) for our primary outcome and moderate quality (certainty) for our secondary outcomes according to GRADE criteria (See <a href="https://archie.cochrane.org/sections/documents/view?version=z1810161445427693100361160184097%26format=REVMAN#SOF-01" target="_blank">Summary of findings table 1</a> and <a href="https://archie.cochrane.org/sections/documents/view?version=z1810161445427693100361160184097%26format=REVMAN#SOF-02" target="_blank">Summary of findings table 2</a>), and would not advocate use of the evidence in this review for clinical decision‐making between the two drugs. </p> </section> <section id="CD002217-sec-0102"> <h3 class="title" id="CD002217-sec-0102">Potential biases in the review process</h3> <p>We were able to include IPD for 635 out of 798 eligible participants (80%), from five out of seven trials in this review and conducted all analyses as IPD analyses. Such an approach has many advantages, such as allowing the standardisation of definitions of outcomes across trials, and attrition and reporting biases are reduced, as we can perform additional analyses and calculate additional outcomes from unpublished data. For the outcomes we used in this review that are of a time‐to‐event nature, an IPD approach is considered to be the 'gold standard' approach to analysis (<a href="./references#CD002217-bbs2-0056" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>). </p> <p>However, despite the advantages of this approach, for reasons out of our control, we were not able to obtain IPD for 163 participants from two eligible trials, and no aggregate data were available for our outcomes of interest in trial publications. We therefore had to exclude 20% of eligible participants from our analyses, which may have introduced bias into the review. Given that no statistically significant differences were found between the drugs in terms of proportions of participants seizure‐free and proportions of participants withdrawing from allocated treatment in the two trials for which IPD were not available (where recorded, see <a href="#CD002217-tbl-0004">Table 2</a>), we do not believe that our conclusions would have changed for the outcomes of this review had the IPD for the seven trials been available. We do however, recommend caution when interpreting results of analyses of this review because of potential retrieval bias from the exclusion of 20% of eligible participants from two trials in this review. </p> <p>We made some assumptions in the statistical methodology used in this review. Firstly, when we received only follow‐up dates and seizure frequencies, we used linear interpolation to estimate seizure times. We are aware that an individual's seizure patterns may be non‐linear; therefore, we recommend caution when interpreting the numerical results of the seizure‐related outcomes. We also made an assumption that treatment effect for each outcome did not change over time (proportional hazards assumption, see <a href="#CD002217-sec-0059">Data synthesis</a>). We are aware that in trials of long duration (e.g. <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> followed up participants for between three and 10 years), the assumption of treatment effect remaining constant over time may not be appropriate. For example, there is likely to be a difference between participants who achieve immediate remission compared with participants who achieve later remission, and we encourage that results should be interpreted with this limitation in mind. </p> </section> <section id="CD002217-sec-0103"> <h3 class="title" id="CD002217-sec-0103">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, together with previous versions of this review, this is the only systematic review and meta‐analysis that compares phenobarbitone and carbamazepine monotherapy for focal onset seizures and generalised onset tonic‐clonic seizures. A network meta‐analysis has been published (<a href="./references#CD002217-bbs2-0044" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonAG . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>), comparing all direct and indirect evidence from phenobarbitone, phenytoin, and other standard and new antiepileptic drugs licensed for monotherapy. The results of this review generally agree with the results of the network meta‐analysis; results of this network meta‐analysis showed a statistically significant advantage for phenytoin compared with phenobarbitone for 'time to treatment failure' for participants with focal onset seizures and no statistically significant differences were found between the drugs for participants with generalised onset seizures or for any of the secondary outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD002217-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD002217-fig-0001" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD002217-fig-0002" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD002217-fig-0003" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure ‐ any reason related to the treatment (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0004" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0005" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Time to treatment failure ‐ any reason related to the treatment, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to adverse events (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0006" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Time to treatment failure due to adverse events (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to adverse events, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0007" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Time to treatment failure due to adverse events, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to lack of efficacy (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0008" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to lack of efficacy, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0009" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy, by epilepsy type (PB: phenobarbitone; PHT: phenytoin) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0010" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Time to first seizure (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0011" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Time to first seizure, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Time to 12 month remission (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0012" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Time to 12 month remission (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Time to 12 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0013" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Time to 12 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG14.png" target="_blank"><b></b></a></p> </div><img alt="Time to 6 month remission (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0014" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Time to 6 month remission (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG15.png" target="_blank"><b></b></a></p> </div><img alt="Time to 6 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)" data-id="CD002217-fig-0015" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Time to 6 month remission, by epilepsy type (PB: phenobarbitone; PHT: phenytoin)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-AFig-FIG16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-AFig-FIG16.png" target="_blank"><b></b></a></p> </div><img alt="Time to 6 month remission ‐ Mattson 1985 (Proportional Hazards Check)" data-id="CD002217-fig-0016" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Time to 6 month remission ‐ <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> (Proportional Hazards Check) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-AFig-FIG16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 1 Time to treatment failure (any reason related to the treatment)." data-id="CD002217-fig-0017" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 1 Time to treatment failure (any reason related to the treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 2 Time to treatment failure due to adverse events." data-id="CD002217-fig-0018" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 2 Time to treatment failure due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 3 Time to treatment failure due to lack of efficacy." data-id="CD002217-fig-0019" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 3 Time to treatment failure due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type." data-id="CD002217-fig-0020" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 5 Time to treatment failure due to adverse events ‐ by epilepsy type." data-id="CD002217-fig-0021" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 5 Time to treatment failure due to adverse events ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type." data-id="CD002217-fig-0022" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 7 Time to treatment failure (any reason related to the treatment) ‐ by age of participants." data-id="CD002217-fig-0023" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 7 Time to treatment failure (any reason related to the treatment) ‐ by age of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 8 Time to treatment failure due to adverse events ‐ by age of participants." data-id="CD002217-fig-0024" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 8 Time to treatment failure due to adverse events ‐ by age of participants. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 9 Time to treatment failure (any reason related to the treatment) ‐ by blinded study design." data-id="CD002217-fig-0025" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 9 Time to treatment failure (any reason related to the treatment) ‐ by blinded study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 10 Time to treatment failure due to adverse events ‐ by blinded study design." data-id="CD002217-fig-0026" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 10 Time to treatment failure due to adverse events ‐ by blinded study design. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 11 Time to first seizure after randomisation." data-id="CD002217-fig-0027" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 11 Time to first seizure after randomisation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 12 Time to first seizure after randomisation ‐ by epilepsy type." data-id="CD002217-fig-0028" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 12 Time to first seizure after randomisation ‐ by epilepsy type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 13 Time to achieve 12‐month remission from seizures." data-id="CD002217-fig-0029" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 13 Time to achieve 12‐month remission from seizures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 14 Time to achieve 12 month remission ‐ by seizure type." data-id="CD002217-fig-0030" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 14 Time to achieve 12 month remission ‐ by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 15 Time to achieve 6‐month remission." data-id="CD002217-fig-0031" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 15 Time to achieve 6‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 16 Time to achieve 6‐month remission ‐ by seizure type." data-id="CD002217-fig-0032" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 16 Time to achieve 6‐month remission ‐ by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD002217-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/urn:x-wiley:14651858:media:CD002217:CD002217-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_t/tCD002217-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 17 Time to achieve 6‐month remission ‐ interval censored." data-id="CD002217-fig-0033" src="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Phenobarbitone (PB) versus phenytoin (PHT) monotherapy, Outcome 17 Time to achieve 6‐month remission ‐ interval censored. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/media/CDSR/CD002217/image_n/nCD002217-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD002217-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly onset focal or generalised epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> phenobarbitone </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenobarbitone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants<sup>a</sup> </i> </p> <p>Range of follow‐up: 0 to 4653 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 2135 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 681 days (1454 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.61</b> </p> <p>(1.22 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>499<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 1.99, 95% CI 1.37 to 2.87, P = 0.0003, I² = 58%), and due to lack of efficacy (HR 1.87, 95% CI 1.32 to 2.66, P = 0.0005, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4653 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1300 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 540 days (760 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.46</b> </p> <p>(1.09 to 1.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>404</p> <p>(3 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 1.86, 95% CI 1.27 to 2.73, P = 0.001, I²=73%), and due to lack of efficacy (HR 1.73 95% CI 1.19 to 2.52, P = 0.004, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 4272 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 10th percentile<sup>d</sup> </p> <p>of time to treatment failure was 778 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 10th percentile<sup>d</sup> of time to treatment failure was 189 days (589 days shorter) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 4.04</b> (1.61 to 10.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,e</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR&lt;1 indicates a clinical advantage for phenobarbitone</p> <p>Treatment failure due to adverse events (HR 4.60, 95% CI 1.17 to 17.98, P = 0.03, I²=0%), and due to lack of efficacy (HR 3.40, 95% CI 1.21 to 9.54, P = 0.02, I² = 0%), also occurred significantly earlier on phenobarbitone compared to phenytoin. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Illustrative risks in the phenobarbitone and phenytoin groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p><b>CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty (quality):</b> Further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty (quality):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty (quality):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very certainty (quality):</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled HR for all participants adjusted for seizure type. All pooled HRs calculated with fixed effects </p> <p>b. Downgraded once for risk of bias: risk of bias judged as high for three unblinded studies as lack of masking may have influenced the withdrawal rates of phenobarbitone </p> <p>c. Downgraded once for inconsistency: Substantial heterogeneity present between studies (I² = 53%); when results are repeated with random effects, confidence intervals around pooled results are fairly wide. Inconsistency may be due to combining studies of an open‐label and double‐blind design. </p> <p>d. The 10th percentile of time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures, as fewer than 50% of participants failed/withdrew from treatment we could not calculate median time. </p> <p>e. Downgraded once for imprecision: the subgroup of participants with generalised onset tonic‐clonic seizures is relatively small (19% of total participants) and confidence intervals around pooled results are fairly wide. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (time to treatment failure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD002217-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults and children with newly onset focal or generalised epilepsy </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> phenobarbitone </p> <p><b>Comparison:</b> phenytoin </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>a</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Certainty (quality) of the evidence</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenytoin</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Phenobarbitone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>All participants<sup>a</sup> </i> </p> <p>Range of follow‐up: 0 to 4589 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 108 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 186 days (78 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.87</b> </p> <p>(0.70 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624</p> <p>(5 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4589 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 74 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 116 days (42 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.81</b> </p> <p>(0.63 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>463<br/> (5 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure (post‐randomisation)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 1 to 4035 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 322 days in the phenytoin group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure post‐randomisation was 439 days (117 days longer) in the phenobarbitone group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.06</b> </p> <p>(0.70 to 1.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenobarbitone</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 4061 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 481 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 483</p> <p>days (2 days longer) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.90</b> </p> <p>(0.69 to 1.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>588<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 4061 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 515 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 483</p> <p>days (32 days shorter) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.96</b> </p> <p>(0.70 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>458<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to achieve 12‐month remission (seizure‐free period)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 8 to 3869 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 375 days in the phenytoin group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to achieve to 12‐month remission was 421</p> <p>days (46 days shorter) in the phenobarbitone group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.77</b> </p> <p>(0.46 to 1.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130<br/> (3 studies)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR &lt; 1 indicates a clinical advantage for phenytoin</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*Illustrative risks in the phenobarbitone and phenytoin groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12‐months of remission) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence</p> <p><b>High certainty (quality):</b> Further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty (quality):</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty (quality):</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very certainty (quality):</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled HR for all participants adjusted for seizure type. All pooled HRs calculated with fixed effects </p> <p>b. Downgraded once for risk of bias: risk of bias judged as high for three unblinded studies as lack of masking may have influenced the withdrawal rates of phenobarbitone </p> <p>c. The HR for individuals with generalised seizures is not estimable from one of the trials as only one participant achieved 12‐month remission </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings ‐ Phenobarbitone compared with phenytoin for epilepsy (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002217-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Male participants:<br/> n (%)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Age at entry (years): Mean (SD), range<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Epilepsy duration<br/> (years): mean (SD),<br/> range<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number of seizures</b> </p> <p><b>in prior 6 months, median (range)<sup>d</sup> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30 (56%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (40%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.1 (3.9)</p> <p>(4 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.5 (3.4)</p> <p>(3 to 16)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.3 (1.8)</p> <p>(0 to 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.0 (2.1)</p> <p>(0 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 170)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 404)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28 (44%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.5 (15.1)</p> <p>(26 to 77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.5 (14.3)</p> <p>(14 to 72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.4 (6.6)</p> <p>(0 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (5.4)</p> <p>(0 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>(1 to 579)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> <p>(1 to 575)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.1 (15.3)</p> <p>(18 to 75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.8 (15.3)</p> <p>(18 to 81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.7 (7.9)</p> <p>(0.5 to 36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.6 (9.1)</p> <p>(0.5 to 59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> <p>(1 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> <p>(1 to 26)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> <p>(61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.4 (6.2)</p> <p>(26 to 55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.8 (2.6)</p> <p>(15 to 26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> <p>(6 to 42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> <p>(6 to 18)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26 (55%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34 (72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23 (50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 (52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.5 (4.8)</p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.3 (5.2)</p> <p>(2 to 18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.8 (3.8)</p> <p>(0.5 to 17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.8 (4.3)</p> <p>0.5 to 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>n: number of participants; NA: not available; PB: phenobarbitone; PHT:phenytoin SD: standard deviation </p> <p>a. Sex was missing for four participants, two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and two participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> (one on PB and one on PHT). Proportions (%) are calculated based on non‐missing data. </p> <p>b. Age at randomisation was missing for two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> <p>c. Epilepsy duration was missing for 41 participants; all 36 participants from <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, two participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>, one participant on PB from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and two participants on PHT from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> <p>d. Number of seizures in the prior six months was missing for 97 participants, all 94 participants from <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> and three participants on PB from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> <p>e. Randomised drug missing for 6 participants in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002217-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes considered and summary of results for trials with no IPD</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number Randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes Reported</b> </p> <p><b> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Summary of Results </b> </p> <p><b> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002217-bbs2-0001" title="CzapinskiP , TerczynskiA , CzapinskaE . Randomised 36‐month comparative study of valproic acid (VPA), phenytoin (PHT), phenobarbital (PHB) and carbamazepine (CBZ) efficacy in patients with newly diagnosed epilepsy with partial complex seizures. Journal of the Neurological Sciences1997;150:162‐3. ">Czapinski 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Proportion achieving 24‐month remission at 3 years</p> <p>2. Proportion "excluded" after randomisation due to adverse effects or no efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. PB: 60% PHT: 59%</p> <p>2. PB: 33% PHT: 23%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD002217-bbs2-0007" title="ThilothammalN , BanuK , RatnamRS . Comparison of phenobarbitone, phenytoin with sodium valproate: randomised, double‐blind study. Indian Pediatrics1996;33(7):549‐55. ">Thilothammal 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Recurrence of Seizures</p> <p>2. Side Effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. PB:16 out of 51 participants (31%) PHT: 14 out of 52 participants (27%)</p> <p>2. PB:17 out of 51 participants (33%) PHT: 33 out of 52 participants (63%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>IPD: individual participant data, PB: phenobarbitone, PHT: phenytoin</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Outcomes considered and summary of results for trials with no IPD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002217-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants contributing to analysis ‐ by epilepsy type</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Trial</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Epilepsy Type</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Number randomised</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to 6‐month and</b> </p> <p><b>12‐month remission<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to 1st seizure<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time to treatment failure</b> </p> <p><b>(any reason, adverse events</b> </p> <p><b> or lack of efficacy)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign=""> <p>Information not available<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>TOTAL</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>347</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>279</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>PB: phenobarbitone, PHT: phenytoin</p> <p>a. Seizure data after randomisation was not available for seven participants (four on PB and three on PHT) in <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a> and for four participants (three on PB and one on PHT) in <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a>. Therefore time to first seizure after randomisation and time to 6‐month and 12‐month remission could not be calculated for these outcomes. </p> <p>b. For <a href="./references#CD002217-bbs2-0006" title="PalDK , DasT , ChaudhuryG , JohnsonAL , NevilleBG . Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet1998;351:19‐23. ">Pal 1998</a> information on time to treatment failure is not available. In <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>, all 36 participants completed the 12‐week trial duration and no participants withdrew from the trial or from the allocated treatment, therefore only time to first seizure after randomisation could be calculated for this trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants contributing to analysis ‐ by epilepsy type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002217-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Reason for early termination</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a><b><sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a><b><sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. "><b>Mattson 1985</b> </a> </p> </td> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PB</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>PHT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Both adverse events and lack of efficacy (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐compliance/protocol violation (event)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Illness or death (not treatment‐related, censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant went into remission (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lost to follow‐up (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other (censored)<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completed the trial (censored)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>55</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>63</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>155</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>165</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>220</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>281</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>501</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>PB: phenobarbitone, PHT: phenytoin<br/> <br/> a. One participant on PHT in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a> has a missing treatment failure time and reason and did not contribute to analysis </p> <p>b. Five participants from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> (three on PB and two on PHT) had missing treatment failure time and did not contribute to analysis, but reasons for treatment failure were provided for the two participants on PHT. </p> <p>c.Other reasons from <a href="./references#CD002217-bbs2-0004" title="MattsonRH , CramerJA , CollinsJF , SmithDB , Delgado‐EscuetaAV , BrowneTR , et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic‐clonic seizures. New England Journal of Medicine1985;313(3):145‐51. ">Mattson 1985</a>: participants developed other medical disorders including neurological and psychiatric disorders </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD002217-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Outcome<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Original analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. "><b>de Silva 1996</b> </a> </p> <p><b>(sensitivity analysis)<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Generalised onset and age at onset &gt; 30 years classified as focal onset</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Generalised onset and age at onset &gt; 30 years classified as uncertain seizure type</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pooled HR (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Test of subgroup</b> </p> <p><b>differences</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure</p> <p>(for any reason related to treatment)<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.46 (1.09 to 1.96), I² = 53% </p> <p><b>G:</b> 4.04 (1.61 to 10.14), I² = 0% </p> <p><b>O:</b> 1.61 (1.22 to 2.12), I² = 53% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 4.25, df = 1, P = 0.04, I² = 76.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.36 (1.01 to 1.84), I² = 0% </p> <p><b>G:</b> 4.22 (1.39 to 12.86), I² = 0% </p> <p><b>O:</b> 1.47 (1.10 to 1.97), I² = 4% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.68, df = 1, P = 0.06, I² = 72.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.54 (1.15 to 2.06), I² = 66% </p> <p><b>G:</b> 3.18 (1.15 to 8.76), I² = 0% </p> <p><b>O:</b> 1.63 (1.23 to 2.15), I² = 48% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.81, df = 1, P = 0.18, I² = 44.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.46 (1.09 to 1.96), I² = 53% </p> <p><b>G:</b> 3.18 (1.15 to 8.76), I² = 0% </p> <p><b>U</b>: 9.08 (1.01 to 81.51), I² = NA </p> <p><b>O</b>: 1.60 (1.21 to 2.11), I² = 44% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 4.52, df = 2, P = 0.10, I² = 55.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to adverse events<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.86 (1.27 to 2.73), I² = 73% </p> <p><b>G:</b> 4.60 (1.17 to 17.98), I² = 0% </p> <p><b>O:</b> 1.99 (1.37 to 2.87), I² = 58% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.57, df = 1, P = 0.21, I² = 36.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.65 (1.11 to 2.46), I² = 27% </p> <p><b>G:</b> 5.04 (1.04 to 24.53), I² = 0% </p> <p><b>O:</b> 1.76 (1.20 to 2.59), I² = 21% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.80, df = 1, P = 0.18, I² = 44.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.92 (1.31 to 2.81), I² = 79% </p> <p><b>G:</b> 3.01 (0.75 to 12.07), I² = 0% </p> <p><b>O:</b> 1.98 (1.37 to 2.86), I² = 59% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.37, df = 1, P = 0.54, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Not available<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to treatment failure due to lack of efficacy<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.73 (1.19 to 2.52), I² = 0% </p> <p><b>G:</b> 3.40 (1.21 to 9.54), I² = 0% </p> <p><b>O:</b> 1.87 (1.32 to 2.66), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.45, df = 1, P = 0.23, I² = 31.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.66 (1.13 to 2.44), I² = 0% </p> <p><b>G:</b> 3.22 (0.85 to 12.21), I² = 0% </p> <p><b>O:</b> 1.75 (1.21 to 2.53), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.88, df = 1, P = 0.35, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.76 (1.22 to 2.55), I² = 0% </p> <p><b>G:</b> 3.44 (1.11 to 10.72), I² = 0% </p> <p><b>O:</b> 1.88 (1.32 to 2.67), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.21, df = 1, P = 0.27, I² = 17.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 1.73 (1.19 to 2.52), I² = 0% </p> <p><b>G:</b> 3.44 (1.11 to 10.72), I² = 0% </p> <p><b>U</b>: 2.46 (0.15 to 39.49), I² = NA </p> <p><b>O</b>: 1.86 (1.31 to 2.64), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.31, df = 2, P = 0.52, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to first seizure<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.81 (0.63 to 1.04), I² = 0% </p> <p><b>G</b>: 1.06 (0.70 to 1.62), I² = 27% </p> <p><b>O:</b> 0.87 (0.70 to 1.08), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.17, df = 1, P = 0.28, I² = 14.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.83 (0.64 to 1.08), I² = 0% </p> <p><b>G:</b> 1.00 (0.65 to 1.55), I² = 5% </p> <p><b>O:</b> 0.87 (0.70 to 1.09), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.50, df = 1 (P = 0.48), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.83 (0.65 to 1.06), I² = 0% </p> <p><b>G:</b> 1.08 (0.65 to 1.79), I² = 0% </p> <p><b>O:</b> 0.87 (0.70 to 1.09), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.81, df = 1, P = 0.37, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.81 (0.63 to 1.04), I² = 0% </p> <p><b>G:</b> 1.08 (0.65 to 1.79), I² = 0% </p> <p><b>U</b>: 1.04 (0.43 to 2.50), I² = 0% </p> <p><b>O</b>: 0.87 (0.69 to 1.08), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.15, df = 2, P = 0.56, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 12‐month remission<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.96 (0.70 to 1.33), I² = 9% </p> <p><b>G:</b> 0.77 (0.46 to 1.28), I² = 0% </p> <p><b>O:</b> 0.90 (0.69 to 1.19), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.53, df = 1, P = 0.47, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.89 (0.63 to 1.24), I² = 3% </p> <p><b>G:</b> 0.78 (0.46 to 1.31), I² = 0% </p> <p><b>O:</b> 0.85 (0.64 to 1.13), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.18, df = 1 (P = 0.67), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.97 (0.72 to 1.31), I² = 8% </p> <p><b>G:</b> 0.54 (0.28 to 1.07), I² = 0% </p> <p><b>O:</b> 0.88 (0.67 to 1.16), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.37, df = 1, P = 0.12, I² = 57.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.96 (0.70 to 1.33), I² = 9% </p> <p><b>G:</b> 0.54 (0.28 to 1.07), I² = 0% </p> <p><b>U</b>: 1.00 (0.43 to 2.32), I² = NA </p> <p><b>O</b>: 0.88 (0.67 to 1.16), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.36, df = 2, P = 0.31, I² = 15.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Time to 6‐month remission<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b>: 0.94 (0.71 to 1.25), I² = 0% </p> <p><b>G:</b> 0.82 (0.52 to 1.29), I² = 30% </p> <p><b>O:</b> 0.91 (0.71 to 1.15), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.27, df = 1, P = 0.60, I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F:</b> 0.89 (0.67 to 1.19), I² = 0% </p> <p><b>G:</b> 0.84 (0.53 to 1.34), I² = 22% </p> <p><b>O:</b> 0.88 (0.69 to 1.12), I² = 0% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.05, df = 1 (P = 0.82), I² = 0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b> 0.93 (0.72 to 1.21)<b>:</b>, I² = 0% </p> <p><b>G:</b> 0.65 (0.35 to 1.20), I² = 45% </p> <p><b>O:</b> 0.88 (0.69 to 1.12), I² = 16% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.10, df = 1, P = 0.29, I² = 8.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>F</b>: 0.94 (0.71 to 1.25), I² = 0% </p> <p><b>G:</b> 0.65 (0.35 to 1.20), I² = 45% </p> <p><b>U</b>: 0.87 (0.40 to 1.88), I² = NA </p> <p><b>O</b>: 0.88 (0.69 to 1.13), I² = 2% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.16, df = 2, P = 0.56, I² = 0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Chi²: Chi² statistic; df: degrees of freedom of Chi² distribution; F: focal epilepsy; G: generalised epilepsy; NA: not applicable; O: overall (all participants); P: P value (&lt; 0.05 are classified as statistically significant); U: uncertain epilepsy. </p> <p>a. For time to treatment failure and time to first seizure, HR &lt; 1 indicates a clinical advantage for carbamazepine and for time to 12‐month and six‐month remission, HR &lt; 1 indicates a clinical advantage for phenobarbitone. All results presented are calculated from fixed‐effect meta‐analysis. </p> <p>b. 33 participants reclassified to focal epilepsy or uncertain epilepsy type from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>. Heterogeneity (I<sup>2</sup>) is not applicable for the uncertain epilepsy type group as only one study (<a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a>) contributes to this estimate. </p> <p>c. 46 participants reclassified to focal epilepsy or uncertain epilepsy type from <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> and <a href="./references#CD002217-bbs2-0005" title="OgunrinO , AdamolekunB , OgunniyiA . Cognitive effects of anti‐epileptic drugs in Nigerians with epilepsy. African Journal of Neurological Sciences2005;24(1):18‐24. ">Ogunrin 2005</a>. </p> <p>d. Sensitivity analysis including only the participants in <a href="./references#CD002217-bbs2-0002" title="deSilvaM , MacArdleB , McGowanM , HughesE , StewartK , NevilleBG . Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet1996;347:709‐13. ">de Silva 1996</a>, who were randomised before the phenobarbitone arm was withdrawn. </p> <p>e. This sensitivity analysis could not be conducted as no individuals with uncertain seizure type withdrew from phenytoin in <a href="./references#CD002217-bbs2-0003" title="HellerAJ , ChestermanP , ElwesRD , CrawfordP , ChadwickD , JohnsonAL , et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. Journal of Neurology, Neurosurgery, and Psychiatry1995;58(1):44‐50. ">Heller 1995</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/full#CD002217-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD002217-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbitone (PB) versus phenytoin (PHT) monotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to treatment failure (any reason related to the treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.22, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to treatment failure due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.39, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Time to treatment failure due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.31, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to treatment failure (any reason related to the treatment) ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.22, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.09, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.04 [1.61, 10.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to treatment failure due to adverse events ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.37, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.27, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [1.17, 17.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time to treatment failure due to lack of efficacy ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.32, 2.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.19, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.40 [1.21, 9.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time to treatment failure (any reason related to the treatment) ‐ by age of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.22, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.09, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.93 [1.65, 9.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time to treatment failure due to adverse events ‐ by age of participants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.39, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Adults only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>436</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.18, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Children only</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.99 [1.99, 17.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Time to treatment failure (any reason related to the treatment) ‐ by blinded study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.22, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Open‐label design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [1.69, 5.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Double‐blind design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.95, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Time to treatment failure due to adverse events ‐ by blinded study design <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [1.39, 2.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Open‐label design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.25 [2.75, 14.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Double‐blind design</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.00, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Time to first seizure after randomisation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.69, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Time to first seizure after randomisation ‐ by epilepsy type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>624</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.70, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.63, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.70, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Time to achieve 12‐month remission from seizures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Time to achieve 12 month remission ‐ by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.69, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.70, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.46, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Time to achieve 6‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.73, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Time to achieve 6‐month remission ‐ by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.71, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Focal onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.71, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Generalised onset seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Time to achieve 6‐month remission ‐ interval censored <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 remission before 300 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 remission at 300 days or later</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.60, 1.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Phenobarbitone (PB) versus phenytoin (PHT) monotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD002217.pub3/references#CD002217-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD002217.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD002217-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD002217-note-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD002217-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD002217-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD002217-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD002217-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002217\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002217\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002217\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD002217\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD002217\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002217.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD002217.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD002217.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD002217.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD002217.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719460299"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002217.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719460303"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD002217.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de94c8fadf55b',t:'MTc0MDcxOTQ2MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 